

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626



PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|      |    |        |   |
|------|----|--------|---|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America  |
| NEWS | 2  | JUN 06 | EPFULL enhanced with 260,000 English abstracts  |
| NEWS | 3  | JUN 06 | KOREAPAT updated with 41,000 documents  |
| NEWS | 4  | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications   |
| NEWS | 5  | JUN 19 | CAS REGISTRY includes selected substances from web-based collections  |
| NEWS | 6  | JUN 25 | CA/CAPLUS and USPAT databases updated with IPC reclassification data  |
| NEWS | 7  | JUN 30 | AEROSPACE enhanced with more than 1 million U.S. patent records   |
| NEWS | 8  | JUN 30 | EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations                      |
| NEWS | 9  | JUN 30 | STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in  |
| NEWS | 10 | JUN 30 | STN AnaVist enhanced with database content from EPFULL  |
| NEWS | 11 | JUL 28 | CA/CAPLUS patent coverage enhanced  |
| NEWS | 12 | JUL 28 | EPFULL enhanced with additional legal status information from the EPOline Register  |
| NEWS | 13 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements   |
| NEWS | 14 | JUL 28 | STN Viewer performance improved   |
| NEWS | 15 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced   |
| NEWS | 16 | AUG 13 | CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998   |
| NEWS | 17 | AUG 15 | CAOLD to be discontinued on December 31, 2008   |
| NEWS | 18 | AUG 15 | CAPLUS currency for Korean patents enhanced   |
| NEWS | 19 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information                   |
| NEWS | 20 | SEP 18 | Support for STN Express, Versions 6.01 and earlier, to be discontinued  |
| NEWS | 21 | SEP 25 | CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances |
| NEWS | 22 | SEP 26 | WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced  |
| NEWS | 23 | SEP 29 | IFICLS enhanced with new super search field   |
| NEWS | 24 | SEP 29 | EMBASE and EMBAL enhanced with new search and display fields  |
| NEWS | 25 | SEP 30 | CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents            |





chain nodes :

21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 23

chain bonds :

2-21 4-17 5-11 21-22 21-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15

15-16 16-17

exact/norm bonds :

1-2 1-5 2-3 2-21 3-4 4-5 4-17 5-11 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 21-22 21-23

isolated ring systems :

containing 1 : 6 : 12 :

G1:C,N

G2:O,S

G3:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 21:CLASS 22:CLASS  
23:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus  
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 0.46       | 0.67    |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:46:28 ON 09 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Oct 2008 VOL 149 ISS 15  
FILE LAST UPDATED: 8 Oct 2008 (20081008/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s L1 SSS full

# REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 07:46:32 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 39686 TO ITERATE

100.0% PROCESSED 39686 ITERATIONS 936 ANSWERS  
SEARCH TIME: 00.00.01



L2 936 SEA SSS FUL L1

L3 35 L2

=> d ibib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 35 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2008:859080 CAPLUS Full-text  
DOCUMENT NUMBER: 149:176324  
TITLE: Preparation of substituted diarylpyrazole derivatives  
for use as cannabinoid-CB1 antagonists and serotonin  
reuptake inhibitors  
INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.  
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.  
SOURCE: PCT Int. Appl., 51pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2008084057   | A1   | 20080717 | WO 2008-EP50181 | 20080109 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,<br>CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,<br>FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,<br>KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,<br>ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,<br>PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,<br>TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW<br>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,<br>IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,<br>TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,<br>TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,<br>AM, AZ, BY, KG, KZ, MD, RU, TJ, TM<br>US 20080214559 A1 20080904 US 2008-970229 20080107<br>PRIORITY APPLN. INFO.: EP 2007-100323 A 20070110<br>US 2007-879533P P 20070110<br>OTHER SOURCE(S): MARPAT 149:176324<br>GI |      |          |                 |          |



AB Title compds. I [X = (un)substituted (un)saturated carbon chain containing 0 to 8 atoms, where one carbon atom may be replaced with N, O, or S; R<sup>1</sup> = H or alkyl; or together with the N atom to which it is attached, and together with part of X, form heterocycloalkyl or heteroaryl; R<sup>2</sup> = an essential structural element of any known cannabinoid-CB<sub>1</sub> antagonist; R<sup>3</sup> = an essential structural element of any known serotonin reuptake inhibitor; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as cannabinoid-CB<sub>1</sub> antagonists and serotonin reuptake inhibitors. Thus, e.g., II was prepared by amination of 4-chloro-1-(5-fluoro-1H-indol-3-yl)butan-1-one (preparation given) with piperazine, followed by reduction and amidation with 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazole-4-carboxylic acid (preparation given). I were evaluated in human cannabinoid-CB<sub>1</sub> receptor binding assays, e.g., II demonstrated a pK<sub>i</sub> values of 7.5. I were disclosed as therapeutic agents for psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders.


IT 1039037-40-5E

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted diarylpyrazole derivs. for use as cannabinoid-CB<sub>1</sub> antagonists and serotonin reuptake inhibitors useful in the treatment of diseases)

RN 1039037-40-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-[4-(5-fluoro-1H-indol-3-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:614722 CAPLUS Full-text  
 DOCUMENT NUMBER: 148:561719  
 TITLE: Preparation of pyrrole derivatives, particularly 4,5-diphenylpyrrole-2-carboxamides, as CB1 cannabinoid receptor antagonists  
 INVENTOR(S): Barth, Francis; Congy, Christian; Hortala, Laurent; Rinaldi, Carmona Murielle  
 PATENT ASSIGNEE(S): Sanofi Aventis, Fr.  
 SOURCE: Fr. Demande, 39pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| FR 2908766  | A1   | 20080523 | FR 2006-10202   | 20061120 |
| WO 2008068423   | A2   | 20080612 | WO 2007-FR1888  | 20071119 |
| WO 2008068423   | A3   | 20080731 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |      |          |                 |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  |      |          |                 |          |

PRIORITY APPLN. INFO.: FR 2006-10202 A 20061120

OTHER SOURCE(S): MARPAT 148:561719  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [A = (un)substituted alkylene, phenylene, benzylene, etc.; R1 = H, alkyl; R2 = (un)substituted alkyl, indanyl, monooxygen, monosulfur, mononitrogen 5-7 membered heterocyclyl, benzhydryl, benzhydrylmethyl, etc.; or NR1R2 = morpholinyl, (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl, piperidin-1-yl, pyrrolidin-1-yl; R3-R8 = independently H, halo, alkoxy, (un)substituted alkyl SO0-2-alkyl, OS00-2-alkyl; R9 = OH, CN, CO2H, NH2 and derivs., CONHNH2, SO2CF3, NHSO2CF3, CONHOH, etc.; their free bases and their acid addition salts, and their hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors (no data) and for treatment of the diseases it implies (no data). Thus, a multi-step synthesis starting from 2-amino-3-butynoic acid was given for pyrrole II (m.p. = 102°). I exhibited an excellent affinity in vitro (IC50 ≤ 5•10-7 M) for the CB1 cannabinoid receptors. The antagonist nature of compds. I was demonstrated by adenylate-

cyclase inhibition models, and toxicity was compatible with therapeutic use (no data). The interaction of I with the brain CB1 receptors was determined using a test of ex vivo binding of [3H]-CP55940 after i.v. injection to mice (no data). The interaction of I with the peripheral CB1 receptors was determined using a test of reversion of the inhibiting effect of CP55940 on gastrointestinal transit after oral administration to mice (no data). Thus, I are useful for treating psychiatric, metabolic, and gastrointestinal disorders, smoking cessation, etc. (no data).

IT 1026666-10-3P, 1'-[[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]-1,4'-bipiperidinyl-4'-carboxamide


1026666-11-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diphenylpyrrole carboxamides as antagonists of CB1 cannabinoid receptors)


RN 1026666-10-3 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



RN 1026666-11-4 CAPLUS

CN 1H-Pyrrole-1-hexanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)-, ethyl ester (CA INDEX NAME)



IT 1026665-87-1P 1026665-88-2P 1026665-90-6P

1026665-91-7P 1026665-92-8P 1026665-93-9P

1026665-95-1P 1026665-96-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES




(Uses)

(preparation of diphenylpyrrole carboxamides as antagonists of CB1 cannabinoid receptors)



RN 1026665-87-1 CAPLUS

CN 1H-Pyrrole-1-hexanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 1026665-88-2 CAPLUS

CN 1H-Pyrrole-1-propanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)- (CA INDEX NAME)




RN 1026665-90-6 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-1-(2-cyanoethyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1026665-89-3

CMF C31 H32 Cl3 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1026665-91-7 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)




RN 1026665-92-8 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[5-(4-bromophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)




RN 1026665-93-9 CAPLUS

CN Methanone, [4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl][5-(4-bromophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]- (CA INDEX NAME)





RN 1026665-95-1 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[3-[(methylsulfonyl)amino]propyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



RN 1026665-96-2 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[3-[(trifluoromethyl)sulfonyl]amino]propyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1209410 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 147:486462  
 TITLE: Preparation of imidazolylicarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators  
 INVENTOR(S): Berger, Richard; Edmondson, Scott; Hansen, Alexa; Zhu, Cheng  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 112pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2007120655 | A2   | 20071025 | WO 2007-US8832  | 20070410 |
| WO 2007120655 | A3   | 20080925 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,

KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,  
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,  
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:


US 2006-791961P

P 20060414


OTHER SOURCE(S):

MARPAT 147:486462

GI



I



II

AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R4 = independently H, halo, alkyl, etc.; R5-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently halo, CN, alkyl, etc.; m = 1-4; n = 0-4; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

IT 1057345-59-1 1057345-61-5


RL: PRPH (Prophetic)

(Preparation of imidazolylcarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators)

RN 1057345-59-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1057345-61-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-, methyl ester (CA INDEX NAME)



IT 954397-95-6P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid  
 954397-96-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate  
 954398-90-6P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid  
 954398-91-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate  
 954398-05-1P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid  
 954398-06-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate  
 954398-11-9P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid  
 954398-12-0P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate  
 954398-16-4P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid  
 954398-17-5P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid trifluoroacetate  
 954398-22-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid  
 954398-23-3P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid trifluoroacetate  
 954398-28-8P 954398-34-6P 954398-47-1P,

3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-1-naphthoic acid 954398-48-2P,  
 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidin-4-yl]-1-naphthoic acid trifluoroacetate 954398-68-6P, 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-1-naphthoic acid 954398-69-7P, 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxypiperidin-4-yl]-1-naphthoic acid trifluoroacetate 954398-71-7P,  
 1-(7-Methoxy-2-naphthyl)-4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperazine 954398-79-9P,  
 3-[4-[[1-(3-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954398-81-3P, Methyl 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate 954398-83-5P, 6-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954398-85-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-isopropyl-1-naphthalenecarboxamide 954398-87-9P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[[1-(pyrrolidinyl)carbonyl]-2-naphthyl]piperazine 954398-89-1P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-1-naphthalenecarboxamide 954398-91-5P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-1-naphthalenecarboxamide 954398-93-7P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[3-[[1-(pyrrolidinyl)carbonyl]-2-naphthyl]piperazine 954398-94-8P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-2-naphthalenecarboxamide 954398-96-0P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-2-naphthalenecarboxamide 954398-98-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-isopropyl-2-naphthalenecarboxamide 954399-00-9P, 3-[4-[[2-(2,4-Difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954399-02-1P, 3-[4-[[1-(3-Hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-04-3P, 3-[4-[[1-(3-Ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-06-5P, 3-[4-[[2-(4-Chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-08-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954399-22-5P 954399-24-7P 954399-26-9P 954399-28-1P 954399-30-5P 954399-32-7P 954399-34-9P 954399-36-1P 954399-38-3P 954399-40-7P 954399-42-9P 954399-44-1P 954399-46-3P 954399-48-5P 954399-51-0P 954399-53-2P 954399-55-4P 954399-57-6P 954399-60-1P 954399-62-1P 954399-66-7P 954399-69-0P 954399-72-5P 954399-75-8P 954399-78-1P 954399-81-6P 954399-84-9P 954399-87-2P 954399-90-7P 954399-93-0P 954399-96-3P 954399-99-6P 954400-02-3P 954400-05-6P 954400-08-9P 954400-11-4P 954400-14-7P 954400-17-0P 954400-20-5P 954400-23-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1

receptor modulators)

RN 954397-95-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954397-96-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954397-95-6

CMF C34 H32 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-00-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)






RN 954398-01-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-00-6

CMF C34 H31 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-05-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-06-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 954398-05-1

CMF C33 H29 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-11-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-12-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-11-9

CMF C33 H28 F2 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-16-4 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-17-5 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 954398-16-4

CMF C33 H29 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-22-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-23-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 954398-22-2

CMF C34 H32 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-28-8 CAPLUS

CN  $\beta$ -D-Glucopyranuronic acid, 1-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenecarboxylate] (CA INDEX NAME)

Absolute stereochemistry.



RN 954398-34-6 CAPLUS


CN D-Aspartic acid, N-[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-33-5

CMF C38 H37 N5 O7

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-47-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954398-48-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-47-1

CMF C35 H32 F N3 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-68-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]- (CA INDEX NAME)




RN 954398-69-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-68-6

CMF C35 H32 F N3 O5



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-77-7 CAPLUS


CN Methanone, [4-(7-methoxy-2-naphthalenyl)-1-piperazinyl][1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)






RN 954398-79-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-81-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)




RN 954398-83-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-85-7 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 954398-87-9 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 954398-89-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl- (CA INDEX NAME)




RN 954398-91-5 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl- (CA INDEX NAME)




RN 954398-93-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthalenyl]-N,N-diethyl- (CA INDEX NAME)




RN 954398-94-8 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl- (CA INDEX NAME)




RN 954398-96-0 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl- (CA INDEX NAME)




RN 954398-98-2 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 954399-00-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-02-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-04-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-06-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 954399-08-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-22-5 CAPLUS

CN Methanone, [4-(7-methoxy-2-naphthalenyl)-1-piperazinyl][1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-77-7

CMF C33 H32 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-24-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-79-9

CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-26-9 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-81-3

CMF C34 H32 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-28-1 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 6-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-83-5

CMF C34 H32 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-30-5 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-85-7

CMF C37 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 954399-32-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-1-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-87-9

CMF C38 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-34-9 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-89-1

CMF C36 H37 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-36-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-91-5

CMF C38 H41 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-38-3 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-94-8

CMF C38 H41 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-40-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthalenyl]-1-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-93-7

CMF C38 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-42-9 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-96-0

CMF C36 H37 N5 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-44-1 CAPLUS  
 CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954398-98-2  
 CMF C37 H39 N5 O3



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 954399-46-3 CAPLUS  
 CN 2-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954399-00-9  
 CMF C33 H28 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-48-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-02-1

CMF C32 H28 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-51-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-50-9

CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-53-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-04-3

CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-55-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 954399-06-5

CMF C33 H29 Cl N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2






RN 954399-57-6 CAPLUS  
 CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954399-08-7  
 CMF C34 H31 F N4 O4



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 954399-60-1 CAPLUS  
 CN 1-Naphthalenecarbonitrile, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954399-59-8  
 CMF C34 H31 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-63-4 CAPLUS

CN Methanesulfonamide, N-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-62-3

CMF C34 H35 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-66-7 CAPLUS  
 CN 2-Propanesulfonamide, N-[3-[4-[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-65-6

CMF C36 H39 N5 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-69-0 CAPLUS  
 CN Methanone, [4-(4-amino-2-naphthalenyl)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-68-9

CMF C33 H33 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-72-5 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(4-(2H-tetrazol-5-yl)-2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-71-4

CMF C34 H32 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-75-8 CAPLUS


CN  $\alpha$ -D-Glucopyranuronic acid, 1-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenecarboxylate], 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-74-7

CMF C40 H40 N4 O10

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-78-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N- $\beta$ -D-galactopyranosyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-77-0  
 CMF C40 H43 N5 O8

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 954399-81-6 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-[4-(hydroxymethyl)phenyl]-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-80-5  
 CMF C34 H32 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-84-9 CAPLUS


CN 2-Propenoic acid, 3-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-83-8

CMF C36 H34 N4 O4

Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-87-2 CAPLUS


CN 1-Naphthalenepropanoic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-

1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
(CA INDEX NAME)

CM 1

CRN 954399-86-1

CMF C36 H36 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-90-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydroxypropyl)-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-89-4

CMF C37 H39 N5 O5





CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-93-0 CAPLUS


CN D-Glucitol, 1-deoxy-1-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-92-9

CMF C40 H45 N5 O8

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-96-3 CAPLUS

CN  $\beta$ -D-Glucopyranose, 2-deoxy-2-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-


methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-95-2

CMF C40 H43 N5 O8

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-99-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-98-5

CMF C40 H41 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-02-3 CAPLUS

CN Propanedioic acid, 2-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-01-2

CMF C37 H35 N5 O7



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-05-6 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(2S)-2,3-dihydroxypropyl]-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-04-5

CMF C37 H39 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-08-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-07-8  
 CMF C40 H43 N5 O6

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 954400-11-4 CAPLUS  
 CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-10-3  
 CMF C37 H39 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-14-7 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(1S,2R,3S,4S)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-3-[4-[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-13-6

CMF C40 H43 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-17-0 CAPLUS


CN L-Aspartic acid, N-[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-16-9

CMF C38 H37 N5 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-20-5 CAPLUS

CN Propanoic acid, 3-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-2-hydroxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-19-2

CMF C37 H37 N5 O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-23-8 CAPLUS

CN 1-Naphthaleneacetic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-22-7

CMF C35 H34 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2






- IT 954397-98-9P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate  
 954398-03-9P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate  
 954398-09-5P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate trifluoroacetate  
 954398-14-2P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate  
 954398-20-0P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoate trifluoroacetate  
 954398-26-6P, Methyl 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoate trifluoroacetate  
 954398-31-3P 954398-65-3P, Methyl 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidin-4-yl]-1-naphthoate trifluoroacetate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1 receptor modulators)  
 RN 954397-98-9 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)



- RN 954398-03-9 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)




RN 954398-09-5 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-08-4

CMF C34 H31 F N4 O4




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954398-14-2 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)




RN 954398-20-0 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-19-7

CMF C34 H31 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954398-26-6 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-25-5

CMF C35 H34 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-31-3 CAPLUS

CN D-Aspartic acid, N-[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 1,4-bis(phenylmethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954398-65-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-64-2

CMF C36 H34 F N3 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L3 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:1207584 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 147:486461

TITLE: Preparation of piperazinylcarbonyl and  
piperidinylcarbonyl imidazoles as cholecystokinin-1  
receptor modulators

INVENTOR(S): Berger, Richard; Edmondson, Scott; Hansen, Alexa; Zhu,  
Cheng

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 125pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2007120688 | A2   | 20071025 | WO 2007-US8901  | 20070410 |
| WO 2007120688 | A3   | 20080717 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,




- AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R4 = independently H, halo, alkyl, etc.; R5-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently (hetero)aryl; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.
- IT 954409-74-6P, (2S)-1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(quinolin-3-yl)-2-piperazinecarboxylic acid trifluoroacetate 954409-88-2P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators)
- RN 954409-74-6 CAPLUS
- CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-73-5

CMF C33 H31 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-88-2 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-(3-quinolinyl)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 954409-73-5P 954409-80-4F, N-Ethyl-(2S)-1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(quinolin-3-yl)piperazine-2-carboxamide trifluoroacetate 954409-82-6P  
 954409-83-7P 954409-85-9P 954409-86-0P  
 954409-93-9P 954409-94-0P 954409-98-4F  
 954409-99-5P 954410-05-0P 954410-15-2F  
 954410-16-3P 954410-17-4P 954410-18-5F  
 954410-33-4F, 4-(4-Carboxy-2-naphthyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinecarboxylic acid trifluoroacetate 954410-55-0P 954410-57-2F  
 954410-59-4P 954410-61-8F 954410-64-1P

954410-66-3P 954410-68-5P 954410-70-9P  
 954410-72-1P 954410-74-3P 954410-76-5P  
 954410-78-7P 954410-80-1P 954410-82-3P  
 954410-84-5P 954410-86-6P 954410-86-7P  
 954410-87-8P 954410-88-9P 954410-90-3P  
 954410-91-4P 954410-93-6P 954410-95-8P  
 954410-97-0P 954410-99-2P 954411-00-8P  
 954411-03-1P 954411-04-2P 954411-06-4P  
 954411-06-6P 954411-11-1P 954411-13-3P  
 954411-15-5P 954411-17-7P 954411-20-2P  
 954411-22-4P 954411-25-7P 954411-28-0P  
 954411-30-4P 954411-33-7P 954411-36-0P  
 954411-38-2P 954411-41-7P 954411-44-0P  
 954411-46-2P 954411-48-4P 954411-49-5P  
 954411-51-9P 954411-53-1P 954411-55-3P  
 954411-59-6P 954411-60-0P 954411-63-3P  
 954411-66-6P 954411-69-9P 954411-71-3P  
 954411-73-5P 954411-74-6P 954411-75-7P  
 954411-83-7P 954411-84-8P 954411-85-9P  
 954411-86-0P 954411-87-1P 954411-88-2P  
 954411-89-3P 954411-90-6P 954411-91-7P  
 954411-92-8P 954411-93-9P 954411-94-0P  
 954411-95-1P 954411-96-2P 954411-97-3P  
 954411-99-5P 954412-00-1P 954412-01-2P  
 954412-03-4P 954412-04-5P 954412-05-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as  
 cholecystokinin-1 receptor modulators)

RN 954409-73-5 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-  
 imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-80-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-  
 imidazol-4-yl]carbonyl]-N-ethyl-4-(3-quinolinyl)-, (2S)-,  
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954409-79-1

CMF C35 H36 N6 O3

Absolute stereochemistry.





CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-82-6 CAPLUS

CN Glycine, N-[[ (2S)-1-[ [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny1)-2-piperazinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-83-7 CAPLUS  
 CN Glycine, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-82-6  
 CMF C35 H34 N6 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 954409-85-9 CAPLUS  
 CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-86-0 CAPLUS  
 CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954409-85-9  
 CMF C35 H35 N5 O5


Absolute stereochemistry.



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 954409-93-9 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[[(1-methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)  
 Absolute stereochemistry.




RN 954409-94-0 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
 (CA INDEX NAME)

CM 1

CRN 954409-93-9  
 CMF C38 H39 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-98-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-99-5 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-98-4  
 CMF C38 H39 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954410-05-0 CAPLUS


CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954410-04-9

CMF C37 H36 N4 O7

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954410-15-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954410-16-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954410-15-2

CMF C37 H36 F N5 O5



Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954410-17-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3*S*)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1*H*-imidazol-4-yl]carbonyl]-3-[[1-(methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A

RN 954410-18-5 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)  
 (CA INDEX NAME)


CM 1

CRN 954410-17-4

CMF C38 H38 F N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954410-33-4 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954410-32-3  
 CMF C36 H33 N3 O6




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 954410-55-0 CAPLUS  
 CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-57-2 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-59-4 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-61-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-64-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-66-3 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-68-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-methyl-4-(3-quinoliny)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-70-9 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-methyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-72-1 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-ethyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-74-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-diethyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-76-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-diethyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-78-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-(1-methylethyl)-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-80-1 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-(1-methylethyl)-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 954410-82-3 CAPLUS

CN 2-Piperazinecarboxamide, N-(1,1-dimethylethyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-84-5 CAPLUS

CN 2-Piperazinecarboxamide, N-(1,1-dimethylethyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-85-6 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-propyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-86-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-propyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-87-8 CAPLUS

CN 2-Piperazinecarboxamide, N-butyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-88-9 CAPLUS

CN 2-Piperazinecarboxamide, N-butyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-90-3 CAPLUS

CN Methanone, [(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]-1-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-91-4 CAPLUS

CN Methanone, [1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]-1-pyrrolidinyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-93-6 CAPLUS

CN Methanone, 1-(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperaziny]-4-morpholinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-95-8 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-dimethyl-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-97-0 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-pentyl-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-99-2 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-hexyl-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-00-8 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-N-2H-tetrazol-5-yl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-03-1 CAPLUS

CN 2-Piperazinecarboxamide, N-cyclopropyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-04-2 CAPLUS

CN 2-Piperazineacetic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-06-4 CAPLUS

CN 2-Piperazineacetic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-08-6 CAPLUS

CN Methanone, 1-[(2R)-2-[(acetyloxy)methyl]-4-(3-quinoliny)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-11-1 CAPLUS

CN Acetic acid, 2-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]methoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-13-3 CAPLUS

CN Acetamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-15-5 CAPLUS

CN Acetamide, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]methyl]- (CA INDEX NAME)




Absolute stereochemistry.



RN 954411-17-7 CAPLUS

CN Propanamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-20-2 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-22-4 CAPLUS

CN Cyclopentanecarboxamide, N-[[ (2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-25-7 CAPLUS

CN Benzamide, N-[[ (2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-28-0 CAPLUS

CN Urea, N-[[ (2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-N'-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-30-4 CAPLUS

CN Urea, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]-N'-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-33-7 CAPLUS

CN Urea, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]-N'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-36-0 CAPLUS

CN Methanesulfonamide, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-38-2 CAPLUS

CN Methanesulfonamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-41-7 CAPLUS

CN Cyclopropanesulfonamide, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-44-0 CAPLUS

CN Glycine, N-[[[(2S)-1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-46-2 CAPLUS

CN Glycine, N-[[[(2R)-1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-48-4 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-[[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954411-49-5 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-(3-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 954411-51-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-53-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-55-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[(1-methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 954411-58-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-60-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-63-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-[(1-methylethyl)amino]-2-oxoethoxy]methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A






RN 954411-66-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[(methylsulfonyl)amino]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-69-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[[(methylamino)carbonyl]amino]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-71-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(acetamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-73-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-74-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-75-7 CAPLUS


CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-83-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)- (CA INDEX NAME)




RN 954411-84-8 CAPLUS

CN Acetic acid, 2-[[[1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-4-piperidinyl]oxy]- (CA INDEX NAME)




RN 954411-85-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-4-piperidinyl]oxy]- (CA INDEX NAME)




RN 954411-86-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(methylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-87-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(dimethylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-88-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(1-methylethyl)amino]carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-89-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[(methylamino)carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 954411-90-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[(dimethylamino)carbonyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidiny]- (CA INDEX NAME)




RN 954411-91-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(cyclopropylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-92-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(ethylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-93-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(phenylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-94-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(diethylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-95-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[[[(carboxymethyl)amino]carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 954411-96-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[[[(carboxymethyl)methylamino]carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-97-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-(1-pyrrolidinylcarbonyl)-2-naphthalenyl]- (CA INDEX NAME)









RN 954412-03-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[[(carboxymethyl)amino]carbonyl]-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954412-04-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-(aminocarbonyl)-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 954412-05-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-(aminocarbonyl)-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



IT 954409-89-3 954410-07-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators)

RN 954409-89-3 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-07-2 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 954409-59-7P 954409-60-0P 954409-61-1P, Benzyl

(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-

3-(hydroxymethyl)piperazine-1-carboxylate 954409-62-2P, Benzyl

(3R)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-

imidazol-4-yl]carbonyl]piperazine-1-carboxylate 954409-77-9P,

Methyl (2S)-1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-

yl]carbonyl]-4-(quinolin-3-yl)piperazine-2-carboxylate trifluoroacetate

954409-91-7P 954409-92-8P 954409-97-3P

954410-00-5P 954410-01-6P 954410-02-7P

954410-03-8P 954410-06-1P 954410-08-3P  
 954410-09-4P 954410-10-7P 954410-11-8P  
 954410-12-9P 954410-13-0P 954410-14-1P  
 954410-20-9P 954410-45-8P, Methyl 4-[4-


[(benzyloxy)carbonyl]-2-naphthyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidine-4-carboxylate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators)

RN 954409-59-7 CAPLUS

CN Methanone, [(2R)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-60-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[(phenylmethoxy)carbonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-61-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-, phenylmethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-62-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-77-9 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-76-8

CMF C34 H33 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-91-7 CAPLUS

CN Methanone, 2-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][(2S)-2-(hydroxymethyl)-4-(3-quinolinyl)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-92-8 CAPLUS

CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-97-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3*S*)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1*H*-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]-, methyl ester,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954409-96-2

CMF C39 H41 N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954410-00-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-01-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[[2-(1,1-dimethylethoxy)-2-oxoethoxy]methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 954410-02-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-03-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A






RN 954410-06-1 CAPLUS  
 CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-[4-[[[tris(1-methylethyl)silyl]oxy)methyl]-2-naphthalenyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-08-3 CAPLUS  
 CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-[4-(hydroxymethyl)-2-naphthalenyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954410-09-4 CAPLUS  
 CN 1-Naphthalenecarboxaldehyde, 3-[(3S)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-10-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-11-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-12-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-(azidomethyl)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-13-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-(aminomethyl)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-14-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 954410-20-9 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 3-[(3*S*)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1*H*-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]-, methyl ester,  
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954410-19-6

CMF C39 H40 F N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954410-45-8 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[[4-(phenylmethoxy)carbonyl]-2-naphthalenyl]-, methyl ester (CA INDEX NAME)




L3 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1207445 CAPLUS Full-text  
 DOCUMENT NUMBER: 147:486460  
 TITLE: Preparation of imidazolylcarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators  
 INVENTOR(S): Duffy, Joseph L.; Edmondson, Scott; Hansen, Alexa; Zhu, Cheng  
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
 SOURCE: PCT Int. Appl., 78pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2007120718   | A2   | 20071025 | WO 2007-US8956  | 20070410 |
| WO 2007120718   | A3   | 20080724 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |      |          |                 |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  |      |          |                 |          |

PRIORITY APPLN. INFO.: US 2006-792134P P 20060414  
 OTHER SOURCE(S): CASREACT 147:486460; MARPAT 147:486460  
 GI



I



II

AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently halo, CN, alkyl, etc.; m = 0-4; n = 0-4; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

IT 954382-77-5P, 1-[[2-(2,4-Difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-79-7P, 1-[[1-(3-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-80-8P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-81-1P, 1-[[1-(3-Hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-82-2P, 1-[[1-(2,3-Dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-83-3E, 1-[[1-(3-Isopropoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-84-4P, 1-[[1-(3-Ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-85-5P, 1-[[1-(4-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-86-6P, 1-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-87-7E, 1-[[1-(3-Ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-88-8P, 1-[[1-(3-Ethoxyphenyl)-2-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-89-9E, 1-[[1-(3-Ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-90-2P, 1-[[1-(3-Ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-91-3P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-92-4P, 1-[[1-(3-Ethoxyphenyl)-2-(4-trifluoromethylphenyl)-1H-imidazol-4-

yl]carbonyl]-4-(2-naphthyl)piperazine 954382-93-5P,  
1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-  
yl]carbonyl]-4-(2-naphthyl)piperazine 954382-98-0P


954383-00-7P 954383-01-8P 954383-02-9P  
954383-03-0P 954383-04-1P 954383-05-2P  
954383-06-3P 954383-07-4P 954383-08-5P  
954383-09-6P 954383-10-9P 954383-11-0P  
954383-12-1P 954383-13-2P 954383-14-3P  
954383-15-4P 954383-16-5P 954383-21-2P  
954383-22-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1  
receptor modulators)


RN 954382-77-5 CAPLUS

CN Methanone, [2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-  
(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-79-7 CAPLUS

CN Methanone, [1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-  
naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-80-0 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-  
naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-81-1 CAPLUS

CN Methanone, [1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-82-2 CAPLUS

CN Methanone, [1-(2,3-dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 954382-83-3 CAPLUS


CN Methanone, [1-[3-(1-methylethoxy)phenyl]-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)






RN 954382-84-4 CAPLUS

CN Methanone, [1-(3-ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-85-5 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-86-6 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-87-7 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-88-8 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-89-9 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-90-2 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-91-3 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-92-4 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 954382-93-5 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-98-0 CAPLUS

CN Methanone, [2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-77-5

CMF C32 H28 F2 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-00-7 CAPLUS

CN Methanone, [1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-79-7

CMF C32 H30 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-01-8 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-80-0

CMF C33 H32 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-02-9 CAPLUS

CN Methanone, [1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-81-1

CMF C31 H28 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-03-0 CAPLUS

CN Methanone, [1-(2,3-dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-82-2

CMF C33 H32 N4 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954383-04-1 CAPLUS  
 CN Methanone, [1-[3-(1-methylethoxy)phenyl]-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-83-3  
 CMF C34 H34 N4 O2



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 954383-05-2 CAPLUS  
 CN Methanone, [1-(3-ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-84-4  
 CMF C33 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-06-3 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-85-5

CMF C32 H30 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 954383-07-4 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-86-6

CMF C32 H29 F N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-08-5 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-87-7

CMF C32 H30 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-09-6 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-88-8

CMF C32 H29 Cl N4 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-10-9 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954382-89-9  
 CMF C32 H29 F N4 O2



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 954383-11-0 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954382-90-2  
 CMF C34 H34 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-12-1 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-91-3

CMF C33 H32 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-13-2 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954382-92-4  
 CMF C33 H29 F3 N4 O2



CM 2  
 CRN 76-05-1  
 CMF C2 H F3 O2



RN 954383-14-3 CAPLUS  
 CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
 CM 1  
 CRN 954382-93-5  
 CMF C33 H31 F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954383-15-4 CAPLUS

CN Methanone, [1-(3-ethoxy-5-fluorophenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954383-16-5 CAPLUS

CN Methanone, [1-(3-ethoxy-5-fluorophenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954383-15-4

CMF C33 H31 F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954383-21-2 CAPLUS

CN Methanone, [1-(3-fluoro-5-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954383-22-3 CAPLUS

CN Methanone, [1-(3-fluoro-5-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954383-21-2

CMF C32 H29 F N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L3 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:11808 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:121964

TITLE: Imidazole based LXR modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Busch, Brest B.; Flatt, Brenton T.; Gu, Xiao Hui; Lu, Shao Po; Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie Lin; Xie, Yinong

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2007002563   | A1   | 20070104 | WO 2006-US24757 | 20060626 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |      |          |                 |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,   |      |          |                 |          |



KG, KZ, MD, RU, TJ, TM

|               |    |          |                 |          |
|---------------|----|----------|-----------------|----------|
| AU 2006261845 | A1 | 20070104 | AU 2006-261845  | 20060626 |
| CA 2613522    | A1 | 20070104 | CA 2006-2613522 | 20060626 |
| EP 1910308    | A1 | 20080416 | EP 2006-785562  | 20060626 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, RS



|                |   |          |                  |          |
|----------------|---|----------|------------------|----------|
| MX 200800141   | A | 20080407 | MX 2008-141      | 20071219 |
| IN 2007DN10015 | A | 20080620 | IN 2007-DN10015  | 20071224 |
| KR 2008039381  | A | 20080507 | KR 2008-701879   | 20080124 |
| CN 101248049   | A | 20080820 | CN 2006-80030791 | 20080222 |

PRIORITY APPLN. INFO.:

|                 |   |          |
|-----------------|---|----------|
| US 2005-694372P | P | 20050627 |
| US 2005-736120P | P | 20051110 |
| WO 2006-US24757 | W | 20060626 |

OTHER SOURCE(S): MARPAT 146:121964

GI



AB Compds. of the invention, such as compds. of formulas I, II, III and IV and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed. Compds. of formulas I - IV wherein R1 is (un)substituted (hetero)aryl, (un)substituted C3-8 cycloalkyl, (un)substituted alkyl, (un)substituted acyl, (un)substituted thioacyl, sulfonyl, ether, etc.; R2 and R21 are independently (un)substituted alkyl, (un)substituted alkylidyl, H, halo, NO2, (hetero)aryl, etc.; R3 is (un)substituted alkyl, (un)substituted alkylidyl, (un)substituted (hetero)aryl, CN, etc.; G is (un)substituted (hetero)aryl, (un)substituted (hetero)biaryl, (un)substituted alkylaryl, etc.; and their pharmaceutically acceptable salts, isomers, and prodrugs thereof are claimed. Example compound V was prepared by addition of 2,5-dichloroaniline to 5-bromothiophene-2-carbonitrile; the resulting 5-bromo-N-(2,5-dichlorophenyl)thiophene-2-carboxamide underwent cyclization with 1-bromo-3,3,3-trifluoroacetone to give 2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-4,5-dihydro-1H-imidazol-4-ol, which underwent dehydration to give 2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-1H-imidazole, which underwent Suzuki

cross-coupling with 3-methylsulfonylphenylboronic acid to give compound V. All the invention compds. were evaluated for their LXR modulatory activity. From the assay, it was determined that several of the tested compound exhibited IC50 values of < 1 µM. Compds. of the invention, such as compds. of Formulas Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed.


IT 518348-97-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole based LXR modulators and their use in the treatment of diseases)

RN 918348-97-7 CAPLUS

CN Methanone, [2-(2,6-dichlorophenyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2006:677655 CAPLUS Full-text

DOCUMENT NUMBER: 145:124571

TITLE: preparation of imidazoles and pyrazoles as CB1 and/or CB2 cannabinoid receptor ligands.

INVENTOR(S): Makriyannis, Alexandros; Thotapally, Rajesh; Vemuri, Venkata Kiran Rao; Olszewska, Teresa

PATENT ASSIGNEE(S): Vemuri, Venkata, Kiran, Rao, USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2006074445 | A2   | 20060713 | WO 2006-US720   | 20060110 |
| WO 2006074445 | A3   | 20060928 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM


AU 2006203845 A1 20060713 AU 2006-203845 20060110  
 CA 2594488 A1 20060713 CA 2006-2594488 20060110  
 EP 1845972 A2 20071024 EP 2006-733658 20060110

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR


JP 2008526887 T 20080724 JP 2007-550544 20060110  
 IN 2007CN03498 A 20071116 IN 2007-CN3498 20070810

PRIORITY APPLN. INFO.: US 2005-642544P P 20050110  
 WO 2006-US720 W 20060110

OTHER SOURCE(S): MARPAT 145:124571  
 GI



I



II

AB Title compds. e.g. [I; A, B = bond, O, (CH2)1R5; B = bond, O, NR5; R5 = H, (substituted) alkyl; l = 0, 1; R1, R2 = (CH2)nZ; n = 0-7; Z = H, halo, N3, NCS, cyano, NO2, OAC, acyloxy, aryloxy, acylamino, alkoxy, substituted carbocyclyl, heterocyclyl, etc.; R3 = specified 5-6 membered ring, bicycloheptyl, adamantyl, fused ring system, etc.; R4 = H, halo, N3, NCS, Ph, cyano, NO2, carbocyclyl, heterocyclyl, aryl, heteroaryl, azabicycloheptyl, etc.], were claimed. Thus, title compound (II) showed CB1 receptor binding with Ki = 1.2 nM.


IT 837924-76-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of imidazoles and pyrazoles as CB1 and/or CB2 cannabinoid receptor ligands)

RN 897924-76-4 CAPLUS

CN Methanone, [1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:543547 CAPLUS Full-text  
 DOCUMENT NUMBER: 145:1063  
 TITLE: Imidazole derivatives for the treatment of dementia and related disorders  
 INVENTOR(S): Fathi, Zahra  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2006060203 | A2   | 20060608 | WO 2005-US42008 | 20051118 |
| WO 2006060203 | A3   | 20061214 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-632025P P 20041130

OTHER SOURCE(S): MARPAT 145:1063

AB The invention discloses imidazole derivs. which are useful in treating dementia and related disorders.


IT 527372-06-1 527372-06-1D, esters and salts  
 527373-26-8 527373-26-8D, esters and salts  
 527378-40-1 527378-40-1D, esters and salts  
 527378-56-9 527378-56-9D, esters and salts  
 527378-73-0 527378-73-0D, esters and salts  
 527378-78-5 527378-78-5D, esters and salts  
 527379-22-2 527379-22-2D, esters and salts  
 527379-58-4 527379-58-4D, esters and salts  
 527380-53-6 527380-53-6D, esters and salts  
 527380-58-1 527380-58-1D, esters and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazole derivs. for treatment of dementia and related disorders, and use with other agents)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-

yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527378-78-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527379-22-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)






RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidiny]- (CA INDEX NAME)



L3 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:543183 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:1062

TITLE: Imidazole derivatives for treating diseases involving cannabinoid receptor dysregulation

INVENTOR(S): Fathi, Zahra

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2006060190   | A2   | 20060608 | WO 2005-US41895 | 20051118 |
| WO 2006060190   | A3   | 20070802 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,   |      |          |                 |          |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2004-632012P

P 20041130

OTHER SOURCE(S): MARPAT 145:1062

AB This invention relates to imidazole derivs. which are useful in treating diseases linked to the modulation of the cannabinoid receptors.


IT 527372-06-1 527373-26-8 527378-40-1  
527378-56-9 527378-73-0 527378-78-5  
527379-22-2 527379-58-4 527380-53-6  
527380-58-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(imidazole derivs. for treating diseases involving cannabinoid receptor dysregulation)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(trifluoromethoxy)phenyl]-1-piperidinyl- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidiny]- (CA INDEX NAME)



L3 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:542774 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:21208

TITLE: Imidazole derivatives for the treatment of psychiatric disorders

INVENTOR(S): Ortiz, Astrid

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2006060202   | A2   | 20060608 | WO 2005-US42007 | 20051118 |
| WO 2006060202   | A3   | 20061214 |                 |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,   |      |          |                 |          |

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-632028P

P 20041130

OTHER SOURCE(S): MARPAT 145:21208

AB The invention discloses imidazole derivs. which are useful in treating psychiatric disorders.

IT 527372-06-1 527372-06-1D, esters and salts

527373-26-8 527373-26-8D, esters and salts

527378-40-1 527378-40-1D, esters and salts

527378-56-9 527378-56-9D, esters and salts

527378-73-0 527378-73-0D, esters and salts

527378-78-5 527378-78-5D, esters and salts

527379-22-2 527379-22-2D, esters and salts

527379-58-4 527379-58-4D, esters and salts

527380-53-6 527380-53-6D, esters and salts

527380-58-1 527380-58-1D, esters and salts


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(imidazole derivs. for treatment of psychiatric disorders, and use with other agents)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-




yl]carbonyl]-1-piperaziny]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperaziny]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



L3 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:542767 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:14783

TITLE: Imidazole derivatives for the treatment of sexual dysfunction

INVENTOR(S): Glombitza, Bernhard

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 21 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: English  
 PATENT INFORMATION: 1

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2006060199 | A2   | 20060608 | WO 2005-US42001 | 20051118 |
| WO 2006060199 | A3   | 20070419 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2004-632001P P 20041130

OTHER SOURCE(S): MARPAT 145:14783


AB This invention relates to imidazole derivs. which are useful in treating sexual dysfunction.

IT 527372-06-1 527373-26-8 527378-40-1  
 527378-56-9 527378-73-0 527378-78-5  
 527379-22-2 527379-58-4 527380-53-6  
 527380-58-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (imidazole derivs. for the treatment of sexual dysfunction)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)



RN 527378-56-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyloxy]- (CA INDEX NAME)



RN 527378-73-0 CAPLUS


CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyloxy][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)






RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



L3 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:380879 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:432814

TITLE: Preparation of 1,5-diheterocyclyl-1H-triazole derivatives as platelet aggregation inhibitors


INVENTOR(S): Kanaya, Naoaki; Fujii, Kunihiro

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 123 pp.

DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 1 Japanese  
 PATENT INFORMATION:


| PATENT NO.             | KIND   | DATE     | APPLICATION NO.  | DATE       |
|------------------------|--|----------|------------------|------------|
| WO 2006043594          | A1   | 20060427 | WO 2005-JP19207  | 20051019   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM   |          |                  |            |
| AU 2005296582          | A1   | 20060427 | AU 2005-296582   | 20051019   |
| CA 2583153             | A1   | 20060427 | CA 2005-2583153  | 20051019   |
| EP 1803719             | A1   | 20070704 | EP 2005-795875   | 20051019   |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR   |          |                  |            |
| CN 101039934           | A  | 20070919 | CN 2005-80035228 | 20051019   |
| NO 2007001826          | A  | 20070614 | NO 2007-1826     | 20070410   |
| KR 2007063530          | A  | 20070619 | KR 2007-708162   | 20070410   |
| MX 200704643           | A  | 20070608 | MX 2007-4643     | 20070418   |
| US 20080125409         | A1   | 20080529 | US 2007-577476   | 20070418   |
| PRIORITY APPLN. INFO.: |  |          | JP 2004-303851   | A 20041019 |
|                        |  |          | WO 2005-JP19207  | W 20051019 |
| OTHER SOURCE(S):       | MARPAT 144:432814  |          |                  |            |
| GI                     |  |          |                  |            |




AB The title compds. represented by the general formula (I) (wherein Ar1, Ar2 = (un)substituted 5- or 6-membered aromatic heterocyclyl; R1, R2 = H, each (un)substituted lower alkyl, alicyclic heterocyclyl, carbamoyl, or NH2 HO; or NR1R2 together represents an (un)substituted 4- to 7-membered alicyclic heterocyclyl optionally containing one N or O atom other than the ring N atom], salts thereof, or solvates of either are prepared These compds. are potent platelet aggregation inhibitors which inhibit neither COX-1 nor COX-2, and are useful for the prevention and treatment of ischemic diseases. Thus, 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4- triazole-3-carboxylic acid was condensed with neopentylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, Et3N, and 1-hydroxybenzotriazole in DMF at room temperature for 48 h to give 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazole-3- carboxylic acid N-

neopentylamide (II). II showed IC<sub>50</sub> of 0.013  $\mu$ M for inhibiting the collagen-induced aggregation of human blood platelet.


IT 887563-88-8P, 1-[[5-(5-Cyano-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-95-6P  
 , 1-[[5-(5-Fluoro-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of 1,5-diheterocycl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)  
 RN 787563-08-0 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884596-95-6 CAPLUS  
 CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)



IT 884597-10-8P, 1-[[5-(5-Aminomethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of 1,5-diheterocycl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)  
 RN 884597-10-8 CAPLUS  
 CN Methanone, [5-[5-(aminomethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)




IT 884596-93-4P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine  
 884596-94-5P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-96-7P  
 , 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-97-8P,  
 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-98-9P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-3,3-difluoroazetidine 884596-99-0P,  
 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methylpiperazine 884597-00-2P,  
 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methyl-3-oxopiperazine 884597-07-3P,  
 (2S)-1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-2-fluoromethylpyrrolidine 884597-08-4P,  
 4-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]morpholine 884597-09-5P, 1-[[5-(5-Carbamoyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884597-11-9P, 1-[[5-(5-Hydroxymethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)


RN 884596-93-4 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-94-5 CAPLUS

CN Methanone, (4-methoxy-1-piperidiny1)[1-(6-methoxy-3-pyridiny1)-5-(5-methyl-2-pyraziny1)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-96-7 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidiny1)[1-(6-methoxy-3-pyridiny1)-5-(2-pyridiny1)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-97-8 CAPLUS

CN Methanone, (4-methoxy-1-piperidiny1)[1-(6-methoxy-3-pyridiny1)-5-(2-pyridiny1)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-98-9 CAPLUS

CN Methanone, (3,3-difluoro-1-azetidiny1)[1-(6-methoxy-3-pyridiny1)-5-(2-pyridiny1)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-99-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 884597-06-2 CAPLUS


CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 884597-07-3 CAPLUS


CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884597-08-4 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 884597-09-5 CAPLUS


CN 3-Pyridinecarboxamide, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884597-11-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[5-[5-(hydroxymethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:126304 CAPLUS Full-text

DOCUMENT NUMBER: 144:212649

TITLE: Preparation of 4,5-diphenylpyrrole-2-carboxamide derivatives as antagonists of CB1 cannabinoid receptors and their therapeutic application

INVENTOR(S): Barth, Francis; Congy, Christian; Hortala, Laurent; Rinaldi Carmona, Murielle

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Fr. Demande, 26 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE     |
|---|------|----------|------------------|----------|
| FR 2874012  | A1   | 20060210 | FR 2004-8773     | 20040809 |
| FR 2874012  | B1   | 20080822 |                  |          |
| AU 2005279086   | A1   | 20060309 | AU 2005-279086   | 20050802 |
| CA 2576717  | A1   | 20060309 | CA 2005-2576717  | 20050802 |
| WO 2006024777   | A1   | 20060309 | WO 2005-FR2015   | 20050802 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                  |          |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  |      |          |                  |          |
| EP 1781636  | A1   | 20070509 | EP 2005-796087   | 20050802 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU   |      |          |                  |          |
| CN 101014588  | A    | 20070808 | CN 2005-80030251 | 20050802 |
| JP 2008509202   | T    | 20080327 | JP 2007-525320   | 20050802 |
| BR 2005014235   | A    | 20080603 | BR 2005-14235    | 20050802 |
| US 20070149596  | A1   | 20070628 | US 2007-625616   | 20070122 |

|                |    |          |                |          |
|----------------|----|----------|----------------|----------|
| US 7381727     | B2 | 20080603 |                |          |
| IN 2007KN00337 | A  | 20070706 | IN 2007-KN337  | 20070131 |
| MX 200701383   | A  | 20070419 | MX 2007-1383   | 20070202 |
| NO 2007001209  | A  | 20070305 | NO 2007-1209   | 20070305 |
| KR 2007054649  | A  | 20070529 | KR 2007-705467 | 20070308 |
| US 20080194581 | A1 | 20080814 | US 2008-102412 | 20080414 |

PRIORITY APPLN. INFO.:

|                |    |          |
|----------------|----|----------|
| FR 2004-8773   | A  | 20040809 |
| WO 2005-FR2015 | W  | 20050802 |
| US 2007-625616 | A1 | 20070122 |

OTHER SOURCE(S):                    MARPAT 144:212649

GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R1 = H, alkyl; R2 = alkyl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, (un)substituted heterocyclyl, phenylalkylene, etc.; or NR1R2 = (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl, piperidin-1-yl, pyrrolidin-1-yl; R3-R8 = independently H, halo, alkyl, alkoxy, CF3, etc.; R9 = alkyl; and their free bases, and their acid addition salts, hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors and for treatment of the diseases it implies. For instance, II (m.p. = 165°) was prepared in 7 steps via cyclization of alkyne III (preparation given) in the presence of I2/K2CO3, Pd-coupling with (2,4-dichlorophenyl)boronic acid, Ts-deprotection, alkylation of the pyrrole IV with MeI in the presence of K2CO3/ester hydrolysis (ester not isolated) and amidation of the acid with N-aminopiperidine. I exhibited an excellent affinity in vitro (IC50 ≤ 5•10<sup>-7</sup> M) for the CB1 cannabinoid receptors. Thus, I are useful for treating psychosis, appetite and gastrointestinal disorders, smoking and alc. cessation, etc.

IT 875667-48-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrrole carboxamide derivs. as antagonists of CB1 cannabinoid receptors)

RN 875667-48-4 CAPLUS

CN Ethanone, 1-[1-[(5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl)carbonyl]-4-phenyl-4-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT:                    12            THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3    ANSWER 14 OF 35    CAPLUS    COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1154377 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:422349  
 TITLE: Preparation of imidazole derivatives for promoting smoking cessation  
 INVENTOR(S): Gardell, Stephen J.  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 176 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2005099705 | A2   | 20051027 | WO 2005-US8904  | 20050318 |
| WO 2005099705 | A3   | 20060119 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-555920P P 20040324  
 OTHER SOURCE(S): MARPAT 143:422349  
 GI



AB The title compds. I [R1, R2 = (un)substituted Ph, alkyl, (un)substituted cyclohexyl, etc.; R3 = H, alkyl, CH2Ph, Cl, Br; X = CONR4R5 (wherein R4 = H, alkyl; R5 = (un)substituted alkyl, bicycloalkyl, CH2Ph, etc.; or NR4R5 = (un)substituted 5-10 membered (un)saturated heterocyclyl), CONHSO2R10 (R10 = (un)substituted alkyl, Ph, benzocyclohexyl, benzocyclopentyl)] which are useful in promoting smoking cessation and maintaining abstinence, were prepared E.g. a 2-step synthesis of II, starting from 2-chloro-N-(4-chlorophenyl)benzenecarboximide and Et 3-bromo-2-oxopentanoate, was given. The pharmaceutical compns. comprising the compound I in combination with one


or more nicotine replacement therapies or one of more nicotinic receptor modulators are disclosed.

IT 527368-74-7P 527368-79-2P 527368-89-4P  
527368-29-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazole derivs. for promoting smoking cessation)


RN 527368-74-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]-4-thiomorpholinyl- (CA INDEX NAME)




RN 527368-79-2 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527368-89-4 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 527380-29-6 CAPLUS  
 CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)



IT 527368-13-4P 527368-24-7P 527368-29-2P  
 527368-32-7P 527368-37-2P 527368-42-9P  
 527368-46-3P 527368-51-0P 527368-61-2P  
 527368-84-9P 527368-98-5P 527369-08-0P  
 527369-13-7P 527371-67-1P 527371-72-8P  
 527371-76-2P 527371-81-9P 527371-87-5P  
 527371-91-1P 527371-96-6P 527372-01-6P  
 527372-06-1P 527372-11-8P 527372-16-3P  
 527372-21-0P 527372-26-5P 527372-32-3P  
 527372-35-6P 527372-41-4P 527372-46-9P  
 527372-49-2P 527372-54-9P 527372-59-4P  
 527372-63-0P 527372-68-5P 527372-73-2P  
 527372-77-6P 527372-82-3P 527372-87-8P  
 527372-92-5P 527372-97-0P 527373-02-0P  
 527373-06-4P 527373-11-1P 527373-16-6P  
 527373-20-2P 527373-26-6P 527373-32-6P  
 527373-36-0P 527373-41-7P 527373-47-3P  
 527373-52-0P 527373-57-5P 527375-32-2P  
 527375-37-7P 527375-42-4P 527377-14-6P  
 527377-19-1P 527377-25-9P 527377-30-6P  
 527377-34-0P 527377-39-5P 527377-44-2P  
 527377-49-7P 527377-54-4P 527377-59-9P  
 527377-63-5P 527377-68-0P 527377-73-7P  
 527377-78-2P 527377-83-9P 527377-87-3P  
 527377-92-0P 527377-97-5P 527378-02-5P  
 527378-07-0P 527378-12-7P 527378-18-3P  
 527378-22-9P 527378-27-4P 527378-32-1P  
 527378-36-5P 527378-40-1P 527378-44-5P  
 527378-48-9P 527378-52-5P 527378-56-9P  
 527378-60-5P 527378-68-3P 527378-73-0P  
 527378-78-5P 527378-83-2P 527378-88-7P  
 527378-93-4P 527378-98-9P 527379-04-0P  
 527379-08-4P 527379-13-1P 527379-18-6P  
 527379-22-2P 527379-27-7P 527379-32-4P  
 527379-37-9P 527379-42-6P 527379-48-2P  
 527379-52-8P 527379-58-4P 527379-63-1P  
 527379-67-5P 527379-70-0P 527379-75-5P  
 527379-80-2P 527379-85-7P 527379-90-4P  
 527380-00-3P 527380-05-8P 527380-09-2P  
 527380-14-9P 527380-19-4P 527380-24-1P


527380-34-3P 527380-38-7P 527380-43-4P  
527380-48-9P 527380-53-6P 527380-58-1P  
868406-23-9P 868406-26-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of imidazole derivs. for promoting smoking cessation)


RN 527368-13-4 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl]-1-  
piperidinyl- (CA INDEX NAME)




RN 527368-24-7 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]-1-  
piperidinyl- (CA INDEX NAME)




RN 527368-29-2 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-  
yl](3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-32-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)




RN 527368-37-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)




RN 527368-42-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)




RN 527368-46-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)




RN 527368-51-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(hydroxymethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 527368-61-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(diethylamino)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527368-84-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][1-oxido-4-thiomorpholinyl]- (CA INDEX NAME)






RN 527368-98-5 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527369-08-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527369-13-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-5-ethyl-1-[4-(1-methylethyl)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527371-67-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2,3-dimethylphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-72-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-76-2 CAPLUS

CN Benzonitrile, 2-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-81-9 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-87-5 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-91-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-96-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-01-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-11-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-((2,4-dichlorophenyl)-1H-imidazol-4-yl)[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 527372-16-3 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-((2,4-dichlorophenyl)-1H-imidazol-4-yl)[4-(cyclohexyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-21-0 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 527372-20-9  
 CME C27 H20 Cl2 F4 N4 O



CM 2  
 CRN 76-05-1  
 CME C2 H F3 O2



RN 527372-26-5 CAPLUS  
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-32-3 CAPLUS  
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-pyrazinyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 527372-31-2

CMF C25 H22 Cl2 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 527372-35-6 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-41-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(6-methyl-2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)


NAME)



● HCl


RN 527372-46-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-49-2 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl



RN 527372-54-9 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-59-4 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-63-0 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinylmethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 527372-68-5 CAPLUS

CN Benzonitrile, 4-{4-[[1-(4-chlorophenyl)-2-(2,5-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl}- (CA INDEX NAME)



RN 527372-73-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-77-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-


difluorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-82-3 CAPLUS


CN Benzonitrile, 2-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-87-8 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-92-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-97-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 527373-02-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-06-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-11-1 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-16-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-(trifluoromethyl)phenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-20-2 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-32-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-((4-fluorophenyl)methyl)hexahydro-1H-1,4-diazepin-1-yl]-, hydrochloride (1:1)  
(CA INDEX NAME)



● HCl

RN 527373-36-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-((4-fluorophenyl)methyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-41-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-47-3 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-cyclohexyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-52-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl] [4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl



RN 527373-57-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-5-methyl-1-(4-nitrophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527375-32-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-37-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527375-42-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 527377-14-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(1,1-dioxido-2-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-19-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thiazolyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527377-25-9 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-30-6 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-34-0 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-39-5 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl)[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-44-2 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-49-7 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-54-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-59-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,6-dimethyl-3-pyridinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-63-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-68-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-difluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-73-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-78-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-83-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-87-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-92-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-97-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-02-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527378-07-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)



RN 527378-12-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)






RN 527378-18-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-22-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-27-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-32-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-((4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl)][4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxy-1-piperidiny]- (CA INDEX NAME)




RN 527378-36-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-((4-chlorophenyl)-5-propyl-1H-imidazol-4-yl)][4-(4-chloro-3-(trifluoromethyl)phenyl)-4-hydroxy-1-piperidiny]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-((4-chlorophenyl)-1H-imidazol-4-yl)][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidiny]- (CA INDEX NAME)




RN 527378-44-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-52-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-60-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-68-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-fluoro-4-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-83-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-88-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-93-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-98-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-04-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxy-3-methylphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-08-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-13-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-18-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4,6-dimethyl-2-pyrimidinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527379-22-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527379-27-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)






RN 527379-32-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethoxy)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-37-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-42-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-48-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-52-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-63-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-67-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-70-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-75-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-80-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(methylthio)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-85-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methyl-2-pyridinyl)-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-90-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-ethyl-4-hydroxy-1-piperidinyl)- (CA INDEX NAME)




RN 527380-00-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-05-8 CAPLUS

CN Methanone, (4-butyl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-09-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-pentyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-14-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-19-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-24-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-34-3 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-38-7 CAPLUS

CN Methanone, [4-(4-bromophenyl)-4-hydroxy-1-piperidinyl] [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-43-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 527380-48-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527380-53-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)






RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)



RN 868406-23-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(1-methylpropyl)-1-piperidinyloxy]- (CA INDEX NAME)




RN 868406-26-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 527384-14-1

CMF C27 H21 Cl2 F3 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L3 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:822141 CAPLUS Full-text  
 DOCUMENT NUMBER: 143:229830  
 TITLE: Preparation of 1,3-oxazole-2-carboxamide derivatives  
 as antagonists of CB1 cannabinoid receptors and their  
 therapeutic application  
 INVENTOR(S): Barth, Francis; Rinaldi Carmonia, Murielle  
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.  
 SOURCE: Fr. Demande, 21 pp.  
 CODEN: FRXXBL  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| FR 2866340    | A1   | 20050819 | FR 2004-1507    | 20040213 |
| FR 2866340    | B1   | 20061124 |                 |          |
| WO 2005080357 | A2   | 20050901 | WO 2005-FR321   | 20050211 |
| WO 2005080357 | A3   | 20051215 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1716142 A2 20061102 EP 2005-717611 20050211  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1918153 A 20070221 CN 2005-80004731 20050211  
 JP 2007522191 T 20070809 JP 2006-552665 20050211  
 US 20070043060 A1 20070222 US 2006-461629 20060801  
 US 7320978 B2 20080122  
 IN 2006KN02314 A 20070525 IN 2006-KN2314 20060814  
 FR 2004-1507 A 20040213  
 WO 2005-FR321 W 20050211


PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 143:229830  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein R1 = H, alkyl; R2 = alkyl, (un)substituted mononitrogen heterocyclyl, phenylalkylene, etc., or NR1R2 = (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl; R3-R8 = independently H, halo, alkyl, CF3, alkoxy, etc.; their free bases or acid addition salts, and their hydrates or solvates] were prepared as antagonists of CB1 cannabinoid receptors and for treatment of the diseases it implies. For instance, II (m.p. = 165°) was prepared in 4 steps by oximation of 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone with NH2OH•HCl, cyclization with monoethyl oxalate chloride in DCM, hydrolysis, and TEA-amidation with 1-aminopiperidine. I exhibited an excellent affinity in vitro (IC50 ≤ 5•10<sup>-7</sup> M) for the CB1 cannabinoid receptors. Thus, I are useful for treating psychosis, appetite and gastrointestinal disorders, smoking and alc. cessation, etc.


IT 862722-84-7P 862722-85-8P 862722-87-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of oxazole carboxamides derivs. as antagonists of CB1 cannabinoid receptors)

RN 862722-84-7 CAPLUS  
 CN Methanone, [5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl][4-(3-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 862722-85-8 CAPLUS

CN Methanone, [5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl](4-hydroxy-4-phenyl-1-piperidiny)- (CA INDEX NAME)



RN 862722-87-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl]carbonyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:497497 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:43882

TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamide derivatives showing CB1-antagonistic activity and combination treatment involving the compounds

INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Gunter; Lange, Josephus Hubertus Maria; Kruse, Cornelis Gerrit

PATENT ASSIGNEE(S): Germany

SOURCE: U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE       |
|------------------------|------|----------|-----------------|------------|
| US 20050124660         | A1   | 20050609 | US 2004-969840  | 20041022   |
| PRIORITY APPLN. INFO.: |      |          | US 2003-513995P | P 20031027 |

OTHER SOURCE(S):  
GI

CASREACT 143:43882; MARPAT 143:43882



AB The present invention relates to a novel medical use of compds. with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivs., 1H-imidazole derivs., thiazole derivs. and/or 1H-1,2,4-triazole-3-carboxamide derivs. or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compds. with CB1-receptor activity in combination with lipase inhibitors. Said compds. are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin. I was prepared and other similar compds. were tested for human cannabinoid CB1 receptor affinity and in vitro antagonism.


IT 676457-12-8P 676457-31-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1H-1,2,4-triazole-3-carboxamide derivs. showing CB1-antagonistic activity)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




L3 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:395074 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:447220  
 TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands  
 INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Guenter; Lange, Josephus Hubertus Maria; Kruse, Chris  
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:


| PATENT NO.             | KIND   | DATE     | APPLICATION NO.  | DATE       |
|------------------------|--|----------|------------------|------------|
| WO 2005039550          | A2   | 20050506 | WO 2004-EP52639  | 20041022   |
| WO 2005039550          | A3   | 20070322 |                  |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |            |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                  |            |
| AU 2004283056          | A1   | 20050506 | AU 2004-283056   | 20041022   |
| CA 2543338             | A1   | 20050506 | CA 2004-2543338  | 20041022   |
| BR 2004015851          | A  | 20070102 | BR 2004-15851    | 20041022   |
| EP 1753413             | A2   | 20070221 | EP 2004-817279   | 20041022   |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK   |          |                  |            |
| JP 2007513872          | T  | 20070531 | JP 2006-536096   | 20041022   |
| CN 1997364             | A  | 20070711 | CN 2004-80030116 | 20041022   |
| MX 2006PA04434         | A  | 20060620 | MX 2006-PA4434   | 20060421   |
| PRIORITY APPLN. INFO.: |  |          | EP 2003-103961   | A 20031024 |
|                        |  |          | EP 2003-103967   | A 20031027 |
|                        |  |          | WO 2004-EP52639  | W 20041022 |
| OTHER SOURCE(S):       | MARPAT 142:447220  |          |                  |            |
| GI                     |  |          |                  |            |

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

- AB The novel use of nitrogen heterocycles I-V [R, R1, R5, R11 = Ph, naphthyl, thienyl, pyridyl, etc.; R2, = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl; R7 = (un)branched alkyl] for treatment of cannabinoid-CB1 receptor related diseases, especially in juveniles, is described. A 4-step synthesis of triazolecarboxamide VI.HCl starting from di-Me aminomalonate.HCl 4-chlorobenzoyl chloride, 2,4-dichloroaniline, and 1-aminopiperidine is given. Furthermore, the invention pertains to the use of I-V in combination with lipase inhibitors. Preferred lipase inhibitors are olistat, panclicins, ATL-962, and/or lipstatin.
- IT 676457-12-9P 676457-31-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of triazolecarboxamides as cannabinoid-CB1 receptor ligands for treatment of drug-induced obesity in juveniles and adolescents)
- RN 676457-12-8 CAPLUS
- CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




- RN 676457-31-1 CAPLUS
- CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




ACCESSION NUMBER: 2005:220141 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:280212  
 TITLE: Preparation of 1H-imidazole-4-carboxamides as CBI agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders  
 INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans, Arnoldus H. J.; Van Stuivenberg, Herman H.  
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.  
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 490,019.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.                        | DATE        |
|---|------|----------|--|-------------|
| US 20050054679  | A1   | 20050310 | US 2004-912171                         | 20040806    |
| US 7109216  | B2   | 20060919 |  |             |
| WO 2003027076   | A2   | 20030403 | WO 2002-EP10434                        | 20020917    |
| WO 2003027076   | A3   | 20031120 |  |             |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |          |  |             |
| US 20040235854  | A1   | 20041125 | US 2004-490019                         | 20040319    |
| US 20050267161  | A1   | 20051201 | US 2005-138289                         | 20050527    |
| PRIORITY APPLN. INFO.:  |      |          | EP 2001-203851                         | A 20010921  |
|   |      |          | WO 2002-EP10434                        | W 20020917  |
|   |      |          | US 2004-490019                         | A2 20040319 |
|   |      |          | US 2004-574939P                        | P 20040528  |
| OTHER SOURCE(S):  |      |          | CASREACT 142:280212; MARPAT 142:280212 |             |
| GI  |      |          |  |             |




I



II



- AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R1 = (un)substituted Ph or pyridinyl; R2 = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R3 = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R3 = pyridinyl or Ph when R4 ≠ H; or R3 = NR5R6 when R2 = H or Me; or NR2R3 = (un)substituted heterocyclyl; R4 = H, halo, CN, carbamoyl, formyl, acetyl, CF3CO, FCH2CO, EtCO, sulfamoyl, MeSO2, MeS, or (un)substituted alkyl; R5 and R6 = independently alkyl; or NR5R6 = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists. For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboxamidine (42%). Cyclization of the carboxamidine with Et 3-bromo-2-oxopropanoate in a solution of NaHCO3 and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarbonyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH2Cl2 afforded II (26%). Selected I bound to hCB1 receptor with pKi values in the range of 7.0 to 8.4. I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).
- IT 505073-33-6P, 1-[[1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]hexahydro-1H-azepine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (CB1 modulator; preparation of imidazolecarboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)
- RN 505073-33-6 CAPLUS
- CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



L3 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:164961 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 142:411290  
 TITLE: Synthesis, Structure-Activity Relationships at the GABAA Receptor in Rat Brain, and Differential Electrophysiological Profile at the Recombinant Human GABAA Receptor of a Series of Substituted 1,2-Diphenylimidazoles

AUTHOR(S): Asproni, Battistina; Talani, Giuseppe; Busonero, Fabio; Pau, Amedeo; Sanna, Sebastiano; Cerri, Riccardo; Mascia, Maria Paola; Sanna, Enrico; Biggio, Giovanni

CORPORATE SOURCE: Dipartimento Farmaco Chimico Tossicologico, Università di Sassari, Sassari, Italy

SOURCE: Journal of Medicinal Chemistry (2005), 48(7), 2638-2645  
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:411290

GI



AB A series of new 1,2-diphenylimidazole derivs. I (R = H, Me, CO<sub>2</sub>H, CO<sub>2</sub>Me, CO<sub>2</sub>Et, CO<sub>2</sub>Pr, CONEt<sub>2</sub>, etc.; X = H, F, Cl, Br, iodo, Me, OMe, NO<sub>2</sub>, NH<sub>2</sub>, NHAc; X<sub>1</sub> = H, 3-Cl, 4-Cl, 4-F, 3,4-Cl<sub>2</sub>, 2,4-Cl<sub>2</sub>) were synthesized and evaluated for their ability to potentiate γ-aminobutyric acid (GABA)-evoked currents in *Xenopus laevis* oocytes expressing recombinant human GABAA receptors. Many of these compds. enhanced GABA action with potencies (EC<sub>50</sub> = 0.19–19 μM) and efficacies (maximal efficacies of up to 640%) similar to or greater than those of anesthetics such as etomidate, propofol, and alphaxalone. Structure-activity relationship anal. revealed that the presence of an ester moiety in the imidazole ring was required for full agonist properties, while modifications made in the Ph rings affected potency and efficacy, with II (X = Br) showing the highest potency. These compds. potentiated the [3H]GABA binding to rat brain membranes, suggesting a site of interaction different from that of GABA. As for etomidate, mutation of asparagine-265 in the β<sub>2</sub> subunit of the GABAA receptor into serine reduced the ability of derivative II (X = Cl) to modulate the GABA function.


IT 850339-41-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and GABA-A receptor binding structure-activity of substituted diphenylimidazoles)

RN 850339-41-2 CAPLUS

CN Methanone, [2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:130306 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:392336

TITLE: Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

AUTHOR(S): Plummer, Christopher W.; Finke, Paul E.; Mills, Sander G.; Wang, Junying; Tong, Xinchun; Doss, George A.; Fong, Tung M.; Lao, Julie Z.; Schaeffer, Marie-Therese; Chen, Jing; Shen, Chun-Pyn; Stribling, D. Sloan; Shearman, Lauren P.; Strack, Alison M.; Van der Ploeg, Lex H. T.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1441-1446

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:392336

GI




AB Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CB1 receptor inverse agonists resulted in the discovery of the two amide derivs. I (X = N, CH) (hCB1 IC50 = 6.1 and 4.0 nM). I also demonstrated efficacy in overnight feeding studies in the rat for reduction in both food intake and overall body weight

IT 489446-71-1P 489446-86-8P 489447-12-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, human cannabinoid receptor type 1 binding affinity, and SAR of diarylimidazolecarboxamides and -oxazolecarboxamides starting from arylaldehydes or ketones and using heterocyclization and amidation as the key steps)


RN 489446-71-1 CAPLUS

CN Methanone, (1-methyl-4,5-diphenyl-1H-imidazol-2-yl)-1-piperidinyl- (CA INDEX NAME)




RN 489446-86-8 CAPLUS

CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



RN 489447-12-3 CAPLUS

CN Methanone, [4,5-bis(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:99481 CAPLUS Full-text  
 DOCUMENT NUMBER: 142:198075  
 TITLE: Preparation of imidazole derivatives as cannabinoid receptor ligands  
 INVENTOR(S): Carpino, Philip A.  
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE                                   | APPLICATION NO. | DATE       |
|---|------|--|-----------------|------------|
| WO 2005009974   | A1   | 20050203                               | WO 2004-IB2442  | 20040719   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW<br>RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |  |                 |            |
| US 20050026983  | A1   | 20050203                               | US 2004-893011  | 20040715   |
| PRIORITY APPLN. INFO.:  |      |  | US 2003-491013P | P 20030730 |
| OTHER SOURCE(S):  |      | CASREACT 142:198075; MARPAT 142:198075 |                 |            |
| GI  |      |  |                 |            |




AB Title compds. I [wherein R<sup>1</sup>, R<sup>2</sup> = (un)substituted (hetero)aryl; R<sup>3</sup>a = H or alkyl; R<sup>3</sup>b = H, (un)substituted (cyclo)alkyl, heterocyclyl or (hetero)aryl; n = 0-2; L = CH<sub>2</sub> or C(O); R<sup>4</sup> = (un)substituted amino or hydrazino; or pharmaceutically acceptable salts or solvates or hydrates thereof or the salts] were prepared as cannabinoid receptor ligands. For example, imidazolecarboxamide II was synthesized via the coupling of the corresponding N-Boc protected acid (preparation given) with piperidine in the presence of EDC-HOBT followed by deprotection with HCl/EtOH. Three tested compds., including II, were found to have binding activities from 1-10 nM against cannabinoid receptor CB<sub>1</sub>. Other biol. properties were also assayed (no data).

The invented compds. are useful in the treatment of diseases linked to the activation of the cannabinoid receptors, such as obesity.

IT 837365-15-8P, [2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-  
((isopropylamino)methyl)-1H-imidazol-4-yl]piperidin-1-ylmethanone  
837365-16-9P, [2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-  
[(isopropylamino)methyl]-1H-imidazol-4-yl]pyrrolidin-1-ylmethanone  
837365-17-9P, [1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-  
[(isopropylamino)methyl]-1H-imidazol-4-yl]piperidin-1-ylmethanone  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(ligand; preparation of imidazolecarboxamides as cannabinoid receptor  
ligands)


RN 837365-15-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-[(1-  
methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX  
NAME)




RN 837365-16-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-[(1-  
methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-pyrrolidinyl- (CA INDEX  
NAME)




RN 837365-17-0 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-[(1-  
methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX  
NAME)



IT 837365-18-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (ligand; preparation of imidazolecarboxamides as cannabinoid receptor  
 ligands)  
 RN 837365-18-1 CAPLUS  
 CN Carbamic acid, [[2-(2-chlorophenyl)-1-(4-chlorophenyl)-4-(1-  
 piperidinylcarbonyl)-1H-imidazol-5-yl]methyl](1-methylethyl)-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:996115 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 141:410930  
 TITLE: Preparation of imidazole derivatives as cyclooxygenase  
 (COX) inhibitors  
 INVENTOR(S): Takahashi, Fumie; Terasaka, Tadashi; Morita, Masataka;  
 Konishi, Nobukiyo; Nakamura, Katsuya  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., '71 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2004099130 | A2   | 20041118 | WO 2004-JP5987  | 20040426 |
| WO 2004099130 | A3   | 20050127 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

CA 2524889 A1 20041118 CA 2004-2524889 20040426

EP 1620406 A2 20060201 EP 2004-729517 20040426

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1784386 A 20060607 CN 2004-80012372 20040426

JP 2006525320 T 20061109 JP 2006-507723 20040426

MX 2005PA11855 A 20060217 MX 2005-PA11855 20051104

US 20070043084 A1 20070222 US 2005-555656 20051104

IN 2005CN03322 A 20070601 IN 2005-CN3322 20051208

PRIORITY APPLN. INFO.: AU 2003-902208 A 20030508


AU 2003-903861 A 20030724

AU 2003-904068 A 20030801


WO 2004-JP5987 W 20040426

OTHER SOURCE(S): MARPAT 141:410930

GI



I



II

AB Title compds. I [wherein R1 = (un)substituted (cyclo)alkyl, carbamoyl, cyano, formyl, carboxy or carbonyl; R2 = hydroxy, halo, cyano, or alkoxy; R3 = alkoxy or amino; X, Y = CH or N; et al., or pharmaceutically acceptable salts thereof], were prepared as cyclooxygenase (COX) inhibitors. E.g., addition reaction of p-anisidine with 6-methoxy-3-pyridinecarbonitrile using NaHMS as base (58.4%) followed by cyclization with 3-bromo-1,1,1-trifluoro-2-propanone (21.5%) gave imidazole II. Tested compds. I, including II, showed effective analgesic activity (coefficient >1.5) on adjuvant arthritis at a dose of 3.2 mg/kg, and selectively inhibited COX-I with IC50 (μM) of <0.01 against COX-I (vs. ≥ 0.1 against COX-II). I are therefore useful for the treatment and/or prevention of the diseases associated with COX, such as inflammation, pain, collagen, autoimmune, immunity, thrombosis, cancer and neurodegenerative diseases.

IT 726196-57-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)

RN 726196-57-2 CAPLUS

CN Methanone, [2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]-1H-imidazol-4-



yl]-1-piperidinyl- (CA INDEX NAME)




IT 726196-58-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)

RN 726196-58-3 CAPLUS

CN Methanone, [1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:927195 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:395556

TITLE: Preparation of azole compounds as platelet aggregation inhibitors

INVENTOR(S): Okayama, Toru; Uoto, Kouichi; Ishiyama, Takashi; Kanaya, Naoaki; Kimura, Youichi; Ishihara, Hiroaki; Watanabe, Toshiyuki; Fujii, Kunihiko

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| WO 2004094407  | A1   | 20041104 | WO 2004-JP5605  | 20040420 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, |      |          |                 |          |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

|   |    |          |                  |          |
|---|----|----------|------------------|----------|
| AU 2004232577   | A1 | 20041104 | AU 2004-232577   | 20040420 |
| CA 2522536  | A1 | 20041104 | CA 2004-2522536  | 20040420 |
| EP 1621537  | A1 | 20060201 | EP 2004-728462   | 20040420 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK |    |          |                  |          |
| CN 1774435  | A  | 20060517 | CN 2004-80010326 | 20040420 |
| NO 2005004854   | A  | 20051115 | NO 2005-4854     | 20051020 |
| MX 2005PA11276  | A  | 20060124 | MX 2005-PA11276  | 20051020 |
| US 20060189591  | A1 | 20060824 | US 2005-553982   | 20051020 |

PRIORITY APPLN. INFO.:

|                |   |          |
|----------------|---|----------|
| JP 2003-115204 | A | 20030421 |
| JP 2004-42859  | A | 20040219 |
| WO 2004-JP5605 | W | 20040420 |

OTHER SOURCE(S): MARPAT 141:395556  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Title compds. Q-X-Y (I) [Q = II, etc.; Ar1, Ar2 = (un)substituted 6-membered aromatic heterocycles; (un)substituted phenyl; R2 = H, halo, etc.; X = carbonyl, thiocarbonyl; Y = III; A = 4-7 membered ring, further detail on said ring is given; R1 = OH, etc.] were prepared For example, EDCI-mediated coupling of 2-(6-methoxy-3-pyridyl)-1-(2-pyridyl)-1H-imidazole-4-carboxylic acid with (3R)-fluoropiperidine hydrochloride afforded compound IV in 44% yield. In platelet aggregation inhibition assays, the IC50 value of compound IV was 0.11 µM. Of note, compds. I inhibit neither COX-1 nor COX-2. Disclosed compds. I are claimed useful for the treatment of ischemia.

IT 787562-41-8P 787562-52-1P 787562-54-3P  
 787562-56-5P 787562-63-4P 787562-66-7P  
 787564-53-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of azole compds. as platelet aggregation inhibitors for treatment of ischemia)


RN 787562-41-8 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-52-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-3-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 787562-54-3 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](2-methyl-1-piperazinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 787562-53-2

CMF C21 H23 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 787562-56-5 CAPLUS

CN Methanone, (3,4-dimethyl-1-piperazinyl)[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-63-4 CAPLUS

CN Methanone, (4,5-diphenyl-2-oxazolyl)(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-66-7 CAPLUS

CN Methanone, [5-(4-fluorophenyl)-4-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787564-53-8 CAPLUS

CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




IT 787562-38-3P 787562-40-7P 787562-42-9P  
 787562-43-0P 787562-45-2P 787562-46-3P  
 787562-47-1P 787562-48-5P 787562-49-6P  
 787562-50-9P 787562-51-0P 787562-55-4P  
 787562-57-6P 787562-58-7P 787562-59-8P  
 787562-60-1P 787562-61-2P 787562-62-3P  
 787562-64-5P 787562-65-6P 787562-67-8P  
 787562-68-9P 787562-69-0P 787562-70-3P  
 787562-71-4P 787562-72-5P 787562-73-6P  
 787562-74-7P 787562-75-8P 787562-76-9P  
 787562-77-0P 787562-78-1P 787562-80-5P  
 787562-81-6P 787562-82-7P 787562-83-8P  
 787562-84-9P 787562-85-0P 787562-86-1P  
 787562-87-2P 787562-88-3P 787562-89-4P  
 787562-90-7P 787562-91-8P 787562-92-9P  
 787562-93-0P 787562-94-1P 787562-95-2P  
 787562-96-3P 787562-97-4P 787562-98-5P  
 787562-99-6P 787563-00-2P 787563-01-3P  
 787563-02-4P 787563-03-5P 787563-04-6P  
 787563-05-7P 787563-06-8P 787563-07-9P  
 787563-08-0P 787563-09-1P 787563-10-4P  
 787563-11-5P 787563-12-6P 787563-13-7P  
 787563-14-8P 787563-15-9P 787563-16-0P  
 787563-17-1P 787563-18-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azole compds. as platelet aggregation inhibitors for treatment of ischemia)


RN 787562-38-3 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[2-phenyl-1-(3-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-40-7 CAPLUS

CN Methanone, (5-methyl-1,2-diphenyl-1H-imidazol-4-yl) (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-42-9 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-43-0 CAPLUS

CN Methanone, [1-(4-fluorophenyl)-2-(6-methoxy-3-pyridinyl)-1H-imidazol-4-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-45-2 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]-4-morpholinyl- (CA INDEX NAME)




RN 787562-46-3 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (2,2,4-trimethyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-47-4 CAPLUS

CN Methanone, [3-(dimethylamino)-1-azetidinyll[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-48-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 787562-49-6 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl) [2-(6-methyl-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-50-9 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-51-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)






RN 787562-55-4 CAPLUS

CN Methanone, (2,4-dimethyl-1-piperazinyl)[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-57-6 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 787562-58-7 CAPLUS

CN Methanethione, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-59-8 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]-4-morpholinyl- (CA INDEX NAME)




RN 787562-60-1 CAPLUS

CN Methanone, (hexahydro-4-methyl-1H-1,4-diazepin-1-yl) [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-61-2 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (tetrahydro-3-methyl-1(2H)-pyrimidinyl)- (CA INDEX NAME)




RN 787562-62-3 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (tetrahydro-2-methyl-1(2H)-pyridazinyl)- (CA INDEX NAME)



RN 787562-64-5 CAPLUS


CN Methanone, (4,5-diphenyl-2-oxazolyl) (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-65-6 CAPLUS

CN Methanone, [4-(6-methoxy-3-pyridinyl)-5-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-67-8 CAPLUS


CN Methanone, [5-(4-fluorophenyl)-4-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 787562-68-9 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](tetrahydro-1,4-oxazepin-4(5H)-yl)- (CA INDEX NAME)




RN 787562-69-0 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 787562-70-3 CAPLUS

CN 2-Piperazinone, 4-[[1-(4-methoxy-3-pyridinyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)




RN 787562-71-4 CAPLUS

CN 2-Piperazinone, 4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 787562-72-5 CAPLUS

CN 2-Piperazinone, 1-methyl-4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 787562-73-6 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-74-7 CAPLUS


CN Methanone, [5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-75-8 CAPLUS

CN Methanone, (4-cyclopropyl-1-piperazinyl) [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-76-9 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-phenyl-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-77-0 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-78-1 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-80-5 CAPLUS

CN Methanone, [3-(dimethylamino)-1-azetidiny][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-81-6 CAPLUS

CN Methanone, [5-(3-fluoro-4-methylphenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-82-7 CAPLUS

CN Methanone, [1-(4-methylphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)




RN 787562-83-8 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 787562-84-9 CAPLUS


CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 787562-85-0 CAPLUS




CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl] (4-methyl-4,7-diazaspiro[2.5]oct-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




RN 787562-86-1 CAPLUS

CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-87-2 CAPLUS


CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-88-3 CAPLUS

CN 2-Azetidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)



RN 787562-89-4 CAPLUS


CN Methanone, [2-[(dimethylamino)methyl]-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-90-7 CAPLUS

CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(4-methoxyphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-91-8 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



RN 787562-92-9 CAPLUS


CN 2-Piperazinone, 4-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-93-0 CAPLUS


CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-4-

morpholinyl- (CA INDEX NAME)




RN 787562-94-1 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)




RN 787562-95-2 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-96-3 CAPLUS


CN 2-Piperazinone, 4-[[1-(4-fluorophenyl)-2-(6-methoxy-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-97-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 787562-98-5 CAPLUS


CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 787562-99-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-00-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-01-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-02-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-03-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 787563-04-6 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-05-7 CAPLUS

CN Methanone, (4-fluoro-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-06-8 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-07-9 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787563-08-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 787563-09-1 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)






RN 787563-10-4 CAPLUS


CN Methanone, [(3S)-3-fluoro-1-pyrrolidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787563-11-5 CAPLUS

CN Methanone, [4-(fluoromethyl)-1-piperidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)



RN 787563-12-6 CAPLUS


CN Methanone, (4,4-difluoro-1-piperidinyl)[5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-13-7 CAPLUS


CN Methanone, [(3R)-3-fluoro-1-piperidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787563-14-8 CAPLUS

CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787563-15-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787563-16-0 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-17-1 CAPLUS


CN Methanone, [5-(5-chloro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



RN 787563-18-2 CAPLUS

CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:790826 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:219202

TITLE: Bioisosteric Replacements of the Pyrazole Moiety of Rimobant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists

AUTHOR(S): Lange, Jos H. M.; van Stuijvenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.

CORPORATE SOURCE: Research Laboratories, Solvay Pharmaceuticals, Weesp, 1381 CP, Neth.

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1823-1838  
CODEN: JMCMAR; ISSN: 0022-2623  
American Chemical Society


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219202

GI




AB Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant. A number of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays. The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class. Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model. Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant. A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.

IT 796875-33-7P 796875-35-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of imidazole, thiazole, and triazole analogs of rimonabant as potent and selective CB1 cannabinoid receptor antagonists)


RN 796875-33-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl](4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 796875-35-9 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl] (3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:633918 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:174163

TITLE: Oxazole derivatives as inhibitors of cyclooxygenase, especially COX-I, and their preparation, pharmaceutical compositions, medicaments, and use as analgesics, etc.

INVENTOR(S): Yamamoto, Hirofumi; Ishida, Junya; Tanabe, Daisuke; Satoh, Shigeki; Sawada, Yuki; Ohkawa, Takehiko; Imamura, Kenichiro; Nakamura, Katsuya

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 257 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO.     | KIND   | DATE     | APPLICATION NO. | DATE     |
|----------------|--|----------|-----------------|----------|
| WO 2004065374  | A1   | 20040805 | WO 2004-JP339   | 20040116 |
| W:             | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI |          |                 |          |
| CA 2513295     | A1   | 20040805 | CA 2004-2513295 | 20040116 |
| US 20040157891 | A1   | 20040812 | US 2004-758253  | 20040116 |

|   |    |          |                  |            |
|---|----|----------|------------------|------------|
| EP 1583749  | A1 | 20051012 | EP 2004-702816   | 20040116   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK |    |          |                  |            |
| JP 2006517535   | T  | 20060727 | JP 2006-500393   | 20040116   |
| CN 1835934  | A  | 20060920 | CN 2004-80002095 | 20040116   |
| MX 2005PA07463  | A  | 20060614 | MX 2005-PA7463   | 20050711   |
| IN 2005CN01899  | A  | 20070706 | IN 2005-CN1899   | 20050811   |
| PRIORITY APPLN. INFO.:  |    |          | AU 2003-900207   | A 20030117 |
|   |    |          | AU 2003-901873   | A 20030331 |
|   |    |          | WO 2004-JP339    | W 20040116 |

OTHER SOURCE(S): MARPAT 141:174163


GI




AB Title compds. I are disclosed [wherein: R1 is H, (un)substituted alk(en/yn)yl, (hetero)aryl, (hetero)cycloalkyl, (un)substituted alk(en/yn)oxy, (un)substituted amino, (un)substituted carbamoyl, cyano, carboxy, OH, SH, halo, etc.; R2 is alkyl, heterocyclyl, alkoxy, cyano; R3, R4 is alkylene, alkenylene, bond; R5 is H, alkyl, (hetero)aryl, alkoxy, acyloxy, OH or derivs., cyano, azido, (un)substituted amino, etc.; X is O, S, SO, or SO2; Y is CH or N; n is 0 or 1; or pharmaceutically acceptable salts thereof]. Compds. I have cyclooxygenase (COX) inhibitory activity, especially against the isoenzyme COX-1. Claimed uses include treatment and prevention of inflammation, pain, collagen diseases, autoimmune diseases, various immunity diseases, thrombosis, cancer, and neurodegenerative diseases, in humans and animals. Over 300 compds. I were prepared in examples, as well as many acyclic intermediates to the oxazole nucleus. Many compds. I were also used as intermediates to other compds. I. Thus, 1-[4-(benzyloxy)phenyl]-2-(4-methoxyphenyl)ethanone underwent a sequence of  $\alpha$ -bromination, substitution of bromo by potassium phthalimide, hydrazinolysis of the imide, amidation of the resultant amine with  $\text{CHF}_2\text{CO}_2\text{H}$ , and cyclocondensation using  $\text{PPh}_3$ , I2, and Et3N, to give invention compound II [R =  $\text{PhCH}_2$ ]. This compound underwent a sequence of debenzoylation, etherification with  $\text{BrCH}_2\text{CO}_2\text{Et}$ , and ester reduction with  $\text{LiAlH}_4$ , to give invention compound II [R =  $\text{HOCH}_2\text{CH}_2$ ] (III), a preferred compound. In an adjuvant arthritis test in rats, III had an ED of 3.2 mg/kg.

In human whole blood assays, III had IC50 values of < 0.01 µM for COX-I and > 0.1 µM for COX-II, showing selectivity for the former.


- IT 735266-75-8P, 1-[[5-[4-(Benzyloxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl]piperidine 735266-76-9P, 4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenol 735267-21-7P, 5-[5-[4-(Benzyloxy)phenyl]-2-(1-piperidinylcarbonyl)-1,3-oxazol-4-yl]-2-methoxypyridine 735267-22-8P, 4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenol 735267-24-0P, tert-Butyl [2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]carbamate 735267-43-1P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride 735267-59-1P, tert-Butyl [2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]carbamate 735267-60-4P, [2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride
- RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (drug candidate and intermediate; preparation of diaryl-substituted oxazole derivs. as selective COX-I inhibitors for use as analgesics)
- RN 735266-75-8 CAPLUS
- CN Methanone, [4-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)



- RN 735266-76-9 CAPLUS
- CN Methanone, [5-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




- RN 735267-21-7 CAPLUS
- CN Methanone, [4-(6-methoxy-3-pyridinyl)-5-[4-(phenylmethoxy)phenyl]-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-22-8 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)



RN 735267-24-0 CAPLUS


CN Carbamic acid, [2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 735267-41-1 CAPLUS


CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl-, hydrochloride (1:?) (CA INDEX NAME)






RN 735267-59-1 CAPLUS

CN Carbamic acid, [2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 735267-60-4 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl-, hydrochloride (1:?) (CA INDEX NAME)




IT 735266-77-0P, 2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethanol 735267-23-9P, 2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethanol 735267-42-2P, N-[2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-

yl]phenoxy]ethyl]methanesulfonamide 735267-43-3F,  
 N-[2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]urea 735267-61-5P, N-[2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]urea 735267-62-6P, N-[2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]methanesulfonamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diaryl-substituted oxazole derivs. as selective COX-I inhibitors for use as analgesics)


RN 735266-77-0 CAPLUS

CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-23-9 CAPLUS

CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-42-2 CAPLUS

CN Methanesulfonamide, N-[2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)




RN 735267-43-3 CAPLUS

CN Urea, N-[2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)




RN 735267-61-5 CAPLUS

CN Urea, N-[2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)



RN 735267-62-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:589415 CAPLUS Full-text

DOCUMENT NUMBER: 141:140441

TITLE: Preparation of imidazole and triazole derivatives useful as selective COX-1 inhibitors

INVENTOR(S): Takahashi, Fumie; Nakagawa, Toshiya; Matsushima, Yuji; Nakamura, Katsuya

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2004060367          | A1   | 20040722 | WO 2003-JP15921 | 20031212   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| AU 2003288746          | A1   | 20040729 | AU 2003-288746  | 20031212   |
| PRIORITY APPLN. INFO.: |  |          | AU 2002-953602  | A 20021230 |
|                        |  |          | AU 2003-901804  | A 20030415 |
|                        |  |          | AU 2003-903928  | A 20030728 |
|                        |  |          | WO 2003-JP15921 | W 20031212 |

OTHER SOURCE(S): MARPAT 141:140441

GI



AB Imidazole and triazole derivs. were prepared for use as selective COX-1 inhibitors for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodegenerative diseases. Thus, 4-PhCH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> was treated with 4-MeOC<sub>6</sub>H<sub>4</sub>CN to give 4-PhCH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>NHC(:NH)C<sub>6</sub>H<sub>4</sub>OMe-4 which was cyclized with BrCH<sub>2</sub>COCF<sub>3</sub> and debenzylated to give the imidazole I. I had IC<sub>50</sub> for COX-1 inhibition of < 0.01 and an analgesic coefficient relative to controls of > 1.5.


IT 726194-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)

RN 726194-47-4 CAPLUS

CN Methanone, [1-[4-(2-hydroxyethoxy)phenyl]-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



IT 726196-57-2P 726196-58-3P 726197-06-4P


726197-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)


RN 726196-57-2 CAPLUS

CN Methanone, [2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726196-58-3 CAPLUS

CN Methanone, [1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726197-06-4 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 726197-20-2 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



IT 726195-26-2P 726195-46-6P 726195-54-6P


726195-64-8P 726195-74-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)


RN 726195-26-2 CAPLUS

CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726195-46-6 CAPLUS

CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 726195-54-6 CAPLUS

CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 726195-64-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 726195-74-0 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:272442 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:303680

TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands



INVENTOR(S): Lange, Josephus H. m.; Kruse, Cornelis G.; McCreary, Andrew C.; Van Stuijvenberg, Herman H.  
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.  
 SOURCE: PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2004026301   | A1   | 20040401 | WO 2003-EP50628 | 20030917   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| EP 1402891  | A1   | 20040331 | EP 2002-78966   | 20020919   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK   |      |          |                 |            |
| US 20040106614  | A1   | 20040603 | US 2003-662477  | 20030916   |
| US 7319110  | B2   | 20080115 |                 |            |
| CA 2491394  | A1   | 20040401 | CA 2003-2491394 | 20030917   |
| AU 2003299024   | A1   | 20040408 | AU 2003-299024  | 20030917   |
| AU 2003299024   | B2   | 20080306 |                 |            |
| BR 2003012020   | A    | 20050322 | BR 2003-12020   | 20030917   |
| EP 1542678  | A1   | 20050622 | EP 2003-797318  | 20030917   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |            |
| JP 2006501275   | T    | 20060112 | JP 2004-537155  | 20030917   |
| RU 2325382  | C2   | 20080527 | RU 2005-103244  | 20030917   |
| IN 2004CN03228  | A    | 20060303 | IN 2004-CN3228  | 20041213   |
| ZA 2005000133   | A    | 20051101 | ZA 2005-133     | 20050106   |
| MX 2005PA02862  | A    | 20050527 | MX 2005-PA2862  | 20050315   |
| NO 2005001870   | A    | 20050603 | NO 2005-1870    | 20050418   |
| HK 1078796  | A1   | 20071012 | HK 2005-110963  | 20051201   |
| PRIORITY APPLN. INFO.:  |      |          | EP 2002-78966   | A 20020919 |
|   |      |          | WO 2003-EP50628 | W 20030917 |

OTHER SOURCE(S): MARPAT 140:303680  
 GI




I

AB The title compds. [I; R, R1 = Ph, naphthyl, thienyl, pyridyl, etc.; R2 = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl] which are potent cannabinoid-CB1 receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of disorders involving cannabinoid neurotransmission, were prepared E.g., a 4-step synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4-triazole-3-carboxamide hydrochloride, starting from di-Me aminomalonate.HCl and 4-chlorobenzoyl chloride, was given. The compds. I were tested for in vitro affinity and in vitro antagonism at human cannabinoid-CB1 receptors. The biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound I is claimed.

IT 676457-12-8P 676457-31-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:153570 CAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 140:391240

TITLE: Potent imidazole and triazole Cbl receptor antagonists related to SR141716  
 AUTHOR(S): Dyck, Brian; Goodfellow, Val S.; Phillips, Teresa; Grey, Jonathan; Haddach, Mustapha; Rowbottom, Martin; Naeve, Gregory S.; Brown, Brock; Saunders, John  
 CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1151-1154  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:391240  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

- AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human Cbl receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N- (hexahydro-1H-azepin-1-yl)-1H-1,2,4-triazole-3-carboxamide (II) and 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol- 2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).
- IT 583208-86-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of imidazolecarboxamides and triazolecarboxamides related to SR 141716 and study of their activity as cannabinoid Cbl receptor antagonists)
- RN 583208-86-8 CAPLUS  
 CN Methanone, [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)






REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:376829 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:385424  
 TITLE: Imidazole-4-carboxamide derivatives, and their preparation and use for treatment of obesity  
 INVENTOR(S): Smith, Roger A.; O'Connor, Stephen J.; Wirtz, Stephan-Nicholas; Wong, Wai C.; Choi, Soongyu; Kluender, Harold C. E.; Su, Ning; Wang, Gan; Achebe, Furahi; Ying, Shihong  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 225 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO.  | DATE        |
|---|------|----------|------------------|-------------|
| WO 2003040107   | A1   | 20030515 | WO 2002-US30545  | 20020924    |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW |      |          |                  |             |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                  |             |
| CA 2459745  | A1   | 20030515 | CA 2002-2459745  | 20020924    |
| AU 2002343423   | A1   | 20030519 | AU 2002-343423   | 20020924    |
| US 20040063691  | A1   | 20040401 | US 2002-255049   | 20020924    |
| US 6960601  | B2   | 20051101 |                  |             |
| EP 1432691  | A1   | 20040630 | EP 2002-780365   | 20020924    |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK   |      |          |                  |             |
| BR 2002012986   | A    | 20040817 | BR 2002-12986    | 20020924    |
| HU 2004002376   | A2   | 20050228 | HU 2004-2376     | 20020924    |
| CN 1599724  | A    | 20050323 | CN 2002-818693   | 20020924    |
| JP 2005508384   | T    | 20050331 | JP 2003-542153   | 20020924    |
| NZ 531841   | A    | 20050930 | NZ 2002-531841   | 20020924    |
| CN 1865248  | A    | 20061122 | CN 2006-10091513 | 20020924    |
| MX 2004PA02037  | A    | 20040607 | MX 2004-PA2037   | 20040303    |
| IN 2004DN00612  | A    | 20070112 | IN 2004-DN612    | 20040310    |
| NO 2004001216   | A    | 20040505 | NO 2004-1216     | 20040323    |
| ZA 2004003035   | A    | 20050421 | ZA 2004-3035     | 20040421    |
| US 20050256167  | A1   | 20051117 | US 2005-133751   | 20050520    |
| PRIORITY APPLN. INFO.:  |      |          | US 2001-324473P  | P 20010924  |
|   |      |          | CN 2002-818693   | A3 20020924 |
|   |      |          | US 2002-255049   | A3 20020924 |
|   |      |          | WO 2002-US30545  | W 20020924  |

OTHER SOURCE(S): MARPAT 138:385424  
 GI



AB The invention relates to imidazole derivs. I, which have been found to suppress appetite and induce weight loss [wherein: R<sup>1</sup>, R<sup>2</sup> = alkyl, (un)substituted Ph, alkyl, naphthyl, benzyl, (un)saturated or aromatic heterocyclyl; R<sup>3</sup> = H, alkyl, benzyl, Cl, or Br; X = (a) CONR<sup>4</sup>R<sup>5</sup> or (b) CONHSO<sup>2</sup>R<sup>10</sup>; (a) R<sup>4</sup> = H or alkyl; R<sup>5</sup> = (un)substituted alkyl, bicycloalkyl, benzyl, phenethyl, piperidinyl or pyrrolidinyl, NR<sup>6</sup>R<sup>7</sup>, etc.; or NR<sup>4</sup>R<sup>5</sup> = (un)substituted (un)saturated heterocyclyl; R<sup>6</sup> = H or alkyl; R<sup>7</sup> = alkyl or (un)substituted Ph; or NR<sup>6</sup>R<sup>7</sup> = (un)substituted (un)saturated heterocyclyl; or (b) R<sup>10</sup> = (un)substituted alkyl, benzocyclohexyl, or benzocyclopentyl; including pharmaceutical salts and esters]. The invention also provides methods for synthesis of the compds., pharmaceutical compns. comprising them, and methods of using such compns. for inducing weight loss and treating obesity and obesity-related disorders. Such disorders include dyslipidemia, hypertriglyceridemia, hypertension, diabetes, syndrome X, atherosclerotic disease, cardiovascular disease, cerebrovascular disease, peripheral vessel disease, cholesterol gallstones, cancer, menstrual abnormalities, infertility, polycystic ovaries, osteoarthritis, and sleep apnea. I are also claimed for use in regulating appetite, treating bulimia, treating CNS disorders, treating cognition and memory disorders, and treating substance or behavioral addiction. I may also be administered or formed into pharmaceutical compns. in combination with other agents for similar treatments, e.g., antiobesity agents, hypolipidemics, and antihypertensives. Approx. 50 synthetic examples of both invention compds. and intermediates are given, and several tables of compds. I (480 total compds.) are provided. For instance, 2-chloro-N-(4-chlorophenyl)benzenecarboximidamide was cyclized with Et 3-bromo-2-oxopentanoate in the presence of K<sub>2</sub>CO<sub>3</sub> to give an imidazole-4-carboxylate ester, which reacted with 1-aminopiperidine in the presence of AlMe<sub>3</sub> to give title compound II. In the fasted-refed acute feeding assay in rats, invention compound III at 10 mg/kg orally reduced food consumption by 31-53% vs. control.

IT 527368-74-7P 527368-79-2P 527368-89-4P  
527380-29-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of imidazolecarboxamide derivs. as antiobesity agents)

RN 527368-74-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]-4-

thiomorpholinyl- (CA INDEX NAME)




RN 527368-79-2 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527368-89-4 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 527380-29-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




IT 527368-13-4P 527368-24-7P 527368-29-2P  
 527368-32-7P 527368-37-2P 527368-42-9P  
 527368-46-3P 527368-51-0P 527368-61-2P  
 527368-84-9P 527368-96-5P 527369-08-0P  
 527369-13-7P 527371-67-1P 527371-72-8P  
 527371-76-2P 527371-61-9P 527371-87-5P  
 527371-91-1P 527371-96-6P 527372-01-6P  
 527372-06-1P 527372-11-8P 527372-16-3P  
 527372-21-0P 527372-26-5P 527372-32-3P  
 527372-35-6P 527372-41-4P 527372-46-9P  
 527372-49-2P 527372-54-9P 527372-59-4P  
 527372-63-0P 527372-68-5P 527372-73-2P  
 527372-77-6P 527372-82-3P 527372-87-8P  
 527372-90-5P 527372-97-0P 527373-02-0P  
 527373-06-4P 527373-11-1P 527373-16-6P  
 527373-20-2P 527373-26-8P 527373-32-6P  
 527373-36-0P 527373-41-7P 527373-47-3P  
 527373-52-0P 527373-57-5P 527375-32-2P  
 527375-37-7P 527375-42-4P 527377-14-6P  
 527377-19-1P 527377-25-9P 527377-30-6P  
 527377-34-0P 527377-39-5P 527377-44-2P  
 527377-49-7P 527377-54-4P 527377-59-9P  
 527377-63-5P 527377-66-0P 527377-73-7P  
 527377-78-2P 527377-83-9P 527377-87-3P  
 527377-92-0P 527377-97-5P 527378-02-5P  
 527378-07-0P 527378-12-7P 527378-18-3P  
 527378-22-9P 527378-27-4P 527378-32-1P  
 527378-36-5P 527378-40-1P 527378-44-5P  
 527378-48-9P 527378-52-5P 527378-56-9P  
 527378-60-5P 527378-62-3P 527378-73-0P  
 527378-76-5P 527378-83-2P 527378-88-7P  
 527378-93-4P 527378-98-9P 527379-04-0P  
 527379-08-4P 527379-13-1P 527379-18-6P  
 527379-22-2P 527379-27-7P 527379-32-4P  
 527379-37-9P 527379-42-6P 527379-48-2P  
 527379-52-8P 527379-56-4P 527379-63-1P  
 527379-67-5P 527379-70-0P 527379-75-5P  
 527379-80-2P 527379-85-7P 527379-90-4P  
 527379-95-9P 527380-00-3P 527380-05-8P  
 527380-09-2P 527380-14-9P 527380-19-4P  
 527380-24-1P 527380-24-3P 527380-38-7P  
 527380-43-4P 527380-48-9P 527380-53-6P  
 527380-56-1P 527384-14-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug candidate; preparation of imidazolecarboxamide derivs. as antiobesity agents)


RN 527368-13-4 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527368-24-7 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



RN 527368-29-2 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)



RN 527368-32-7 CAPLUS


CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][3,6-dihydro-4-phenyl-1(2H)-pyridinyl]- (CA INDEX NAME)






RN 527368-37-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-42-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-46-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-51-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(hydroxymethyl)-1-piperidinyl]- (CA INDEX NAME)



RN 527368-61-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(diethylamino)-1-pyrrolidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527368-84-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][1-oxido-4-thiomorpholinyl]- (CA INDEX NAME)




RN 527368-98-5 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527369-08-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527369-13-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-5-ethyl-1-[4-(1-methylethyl)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527371-67-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,3-dimethylphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-72-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-76-2 CAPLUS

CN Benzonitrile, 2-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-81-9 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-87-5 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-91-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] [4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-96-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-01-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-11-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 527372-16-3 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(cyclohexyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-21-0 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl][4-(4-(trifluoromethyl)phenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 527372-20-9  
 CME C27 H20 Cl2 F4 N4 O



CM 2  
 CRN 76-05-1  
 CME C2 H F3 O2



RN 527372-26-5 CAPLUS  
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527372-32-3 CAPLUS  
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-pyrazinyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)



CM 1

CRN 527372-31-2

CMF C25 H22 Cl2 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 527372-35-6 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-41-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(6-methyl-2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)


NAME)



● HCl


RN 527372-46-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-49-2 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-54-9 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-59-4 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-63-0 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinylmethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 527372-68-5 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,5-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-73-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-77-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-


difluorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-82-3 CAPLUS


CN Benzonitrile, 2-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-87-8 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-92-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-97-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 527373-02-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-06-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-11-1 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-16-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-(trifluoromethyl)phenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-20-2 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)





RN 527373-32-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-36-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-41-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-47-3 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-cyclohexyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-52-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl] [4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-57-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-5-methyl-1-(4-nitrophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527375-32-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-37-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527375-42-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 527377-14-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(1,1-dioxido-2-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-19-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thiazolyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527377-25-9 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-30-6 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-34-0 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-39-5 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl)[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-44-2 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-49-7 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-54-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-59-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,6-dimethyl-3-pyridinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-63-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-68-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-difluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-73-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527377-78-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527377-83-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)






RN 527377-87-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-92-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-97-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-02-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-07-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-12-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-18-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-22-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-27-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-32-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-36-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-44-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-52-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-60-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-68-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-fluoro-4-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-83-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-88-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527378-93-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)



RN 527378-98-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)






RN 527379-04-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxy-3-methylphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-08-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-13-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-18-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4,6-dimethyl-2-pyrimidinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-27-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-32-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethoxy)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-37-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-42-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidiny]- (CA INDEX NAME)




RN 527379-48-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-52-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-63-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-67-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-70-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-75-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-80-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(methylthio)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-85-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methyl-2-pyridinyl)-1-piperidinyloxy]- (CA INDEX NAME)




RN 527379-90-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-ethyl-4-hydroxy-1-piperidinyl)- (CA INDEX NAME)




RN 527379-95-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-hydroxy-4-(2-methylpropyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527380-00-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-05-8 CAPLUS

CN Methanone, (4-butyl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)



RN 527380-09-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-pentyl-1-piperidinyl)- (CA INDEX NAME)



RN 527380-14-9 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)






RN 527380-19-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-24-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-34-3 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-38-7 CAPLUS

CN Methanone, [4-(4-bromophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-43-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527380-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidiny]- (CA INDEX NAME)



RN 527384-14-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:261815 CAPLUS Full-text

DOCUMENT NUMBER: 138:287674

TITLE: Preparation of 1H-imidazole-4-carboxamides as CB1

agonists, partial agonists, or antagonists for

treatment of psychiatric and neurological disorders

INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans,

Arnoldus H. J.; Van Stuivenberg, Herman H.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO.    | KIND   | DATE     | APPLICATION NO.  | DATE     |
|---------------|--|----------|------------------|----------|
| WO 2003027076 | A2   | 20030403 | WO 2002-EP10434  | 20020917 |
| WO 2003027076 | A3   | 20031120 |                  |          |
| W:            | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                  |          |
| RW:           | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                  |          |
| TW 231757     | B  | 20050501 | TW 2002-91119798 | 20020830 |
| CA 2457444    | A1   | 20030403 | CA 2002-2457444  | 20020917 |
| AU 2002337106 | A1   | 20030407 | AU 2002-337106   | 20020917 |
| AU 2002337106 | B2   | 20070517 |                  |          |
| EP 1438296    | A2   | 20040721 | EP 2002-772314   | 20020917 |
| R:            | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK   |          |                  |          |
| BR 2002012481 | A  | 20040824 | BR 2002-12481    | 20020917 |
| CN 1556703    | A  | 20041222 | CN 2002-818346   | 20020917 |
| JP 2005504805 | T  | 20050217 | JP 2003-530667   | 20020917 |
| HU 2004002150 | A2   | 20050228 | HU 2004-2150     | 20020917 |
| HU 2004002150 | A3   | 20050829 |                  |          |
| RU 2299200    | C2   | 20070520 | RU 2004-111979   | 20020917 |


|                |    |          |                |          |
|----------------|----|----------|----------------|----------|
| IN 2004CN00574 | A  | 20060113 | IN 2004-CN574  | 20040317 |
| ZA 2004002188  | A  | 20050429 | ZA 2004-2188   | 20040318 |
| NO 2004001171  | A  | 20040621 | NO 2004-1171   | 20040319 |
| US 20040235854 | A1 | 20041125 | US 2004-490019 | 20040319 |
| MX 2004PA02669 | A  | 20040618 | MX 2004-PA2669 | 20040322 |
| US 20050054679 | A1 | 20050310 | US 2004-912171 | 20040806 |
| US 7109216     | B2 | 20060919 |                |          |

PRIORITY APPLN. INFO.:

|                 |    |          |
|-----------------|----|----------|
| EP 2001-203851  | A  | 20010921 |
| WO 2002-EP10434 | W  | 20020917 |
| US 2004-490019  | A2 | 20040319 |
| US 2004-574939P | P  | 20040528 |

OTHER SOURCE(S): MARPAT 138:287674

GI



AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R<sup>1</sup> = (un)substituted Ph or pyridinyl; R<sup>2</sup> = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R<sup>3</sup> = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R<sup>3</sup> = pyridinyl or Ph when R<sup>4</sup> ≠ H; or R<sup>3</sup> = NR<sup>5</sup>R<sup>6</sup> when R<sup>2</sup> = H or Me; or NR<sup>2</sup>R<sup>3</sup> = (un)substituted heterocyclyl; R<sup>4</sup> = H, halo, CN, carbamoyl, formyl, acetyl, CF<sub>3</sub>CO, FCH<sub>2</sub>CO, EtCO, sulfamoyl, MeSO<sub>2</sub>, MeS, or (un)substituted alkyl; R<sup>5</sup> and R<sup>6</sup> = independently alkyl; or NR<sup>5</sup>R<sup>6</sup> = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists (no data). For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboxamide (42%). Cyclization of the carboxamide with Et 3-bromo-2-oxopropanoate in a solution of NaHCO<sub>3</sub> and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarbonyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH<sub>2</sub>Cl<sub>2</sub> afforded II (26%). I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).


IT 505073-33-6P, 1-[[1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]hexahydro-1H-azepine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CB1 modulator; preparation of imidazolecarboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)

RN 505073-33-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-

yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)




IT 796875-33-7

RL: PRPH (Prophetic)

(Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders)

RN 796875-33-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl](4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



L3 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:76555 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:122647

TITLE: Preparation of 4,5-diarylimidazole derivatives as cannabinoid receptor modulators

INVENTOR(S): Finke, Paul E.; Mills, Sander G.; Plummer, Christopher W.; Shah, Shrenik K.; Truong, Quang T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

|                        |  |          |                 |             |
|------------------------|--|----------|-----------------|-------------|
| WO 2003007887          | A2   | 20030130 | WO 2002-US23230 | 20020716    |
| WO 2003007887          | A3   | 20030417 |                 |             |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |          |                 |             |
| RW:                    | GH, GM, GE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |             |
| AU 2002319627          | A1   | 20030303 | AU 2002-319627  | 20020716    |
| US 20030114495         | A1   | 20030619 | US 2002-198442  | 20020717    |
| US 7057051             | B2   | 20060606 |                 |             |
| US 20060089356         | A1   | 20060427 | US 2005-265850  | 20051103    |
| PRIORITY APPLN. INFO.: |  |          | US 2001-307224P | P 20010720  |
|                        |  |          | WO 2002-US23230 | W 20020716  |
|                        |  |          | US 2002-198442  | A3 20020717 |
| OTHER SOURCE(S):       | MARPAT 138:122647  |          |                 |             |
| GI                     |  |          |                 |             |



AB The use of the title compds. [I; R1 = H, cycloalkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10 alkyl, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl; R2 = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10 alkyl, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl, ORD, NRdRe, NRdS(O)mRe; wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted; Rd, Re = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl; or Rd and Re together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 addnl. heteroatoms independently selected from oxygen, sulfur and NRd; Ar1, Ar2 = (un)substituted Ph, naphthyl, thienyl, furanyl, pyrrolyl, benzothienyl, benzofuranyl, indanyl, indenyl, indolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, or 1,4-benzodioxanyl] of the present invention as antagonists and/or inverse agonists of the cannabinoid-1 (CB1)receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor is disclosed. The invention is concerned with the use of these novel compds. to selectively antagonize the Cannabinoid-1 (CB1) receptor (no data). As such, the compds. I are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and

schizophrenia. The compds. I are also useful for the treatment of substance abuse disorders, particularly to opiates, alc., and nicotine. The compds. I are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Thus, benzoin was cyclocondensed with N-methylurea in ethylene glycol at 180° for 1.5 h to give 4,5-diphenyl-1-methyl-2,3-dihydroimidazol-2-one which was heated with POC13 at 100° for 20 h to give 2-chloro-4,5-diphenyl-1- methylimidazole (II). Lithiation of II in THF with 1.6 N BuLi/hexane at -20° for 2 h followed by reaction with benzyl chloroformate at -20° for 20 min and warming the reaction mixture from -20° to room temperature over 30 min gave benzyl 4,5-diphenyl-1-methylimidazole-2- carboxylate which was hydrogenolyzed over 20% Pd/C in methanol at 40 psi for 1 h and condensed with 1-aminopiperidine containing a small percent of piperidine using ByBOP and N,N-diisopropyl-N-ethylamine in CH2Cl2 at room temperature for 20 h to give N-(piperidin-1-yl)-4,5-diphenyl-1-methylimidazole-2- carboxamide and 2-(piperidin-1-ylcarbonyl)-4,5-diphenyl-1-methylimidazole.


IT 489446-71-1P, 2-(Piperidin-1-ylcarbonyl)-4,5-diphenyl-1-methylimidazole 489446-86-3P, 2-(Piperidin-1-ylcarbonyl)-4,5-di(4-methylphenyl)-1-methylimidazole 489446-90-4P, 2-(Pyrrolidin-1-ylcarbonyl)-4,5-di(4-methylphenyl)-1-methylimidazole 489447-12-3P, 2-(Piperidin-1-ylcarbonyl)-4,5-di(4-chlorophenyl)-1-methylimidazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylimidazole derivs. as cannabinoid receptor modulators for prevention or treatment of diseases mediated by cannabinoid-1 receptor)


RN 489446-71-1 CAPLUS

CN Methanone, (1-methyl-4,5-diphenyl-1H-imidazol-2-yl)-1-piperidinyl- (CA INDEX NAME)



RN 489446-86-8 CAPLUS


CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)






RN 489446-90-4 CAPLUS

CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 489447-12-3 CAPLUS

CN Methanone, [4,5-bis(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:702237 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:362533

TITLE: Synthesis and Pharmacological Evaluation of 1-[(1,2-Diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with Clozapine-Like Mixed Activities at Dopamine D2, Serotonin, and GABAA Receptors  
Asproni, Battistina; Pau, Amedeo; Bitti, Mauro; Melosu, Marilena; Cerri, Riccardo; Dazzi, Laura; Seu, Emanuele; Maciocco, Elisabetta; Sanna, Enrico; Busonero, Fabio; Talani, Giuseppe; Pusceddu, Luca; Altomare, Cosimo; Trapani, Giuseppe; Biggio, Giovanni

AUTHOR(S): Dipartimento Farmaco Chimico Tossicologico, Facolta di Farmacia, Universita degli Studi di Sassari, Sassari, 07100, Italy

SOURCE: Journal of Medicinal Chemistry (2002), 45(21), 4655-4668

CODEN: JMCNAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:362533

AB A series of 18 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-piperazines were designed and synthesized as possible ligands with mixed dopamine (DA)

D2/serotonin 5-HT1A affinity, with the aim of identifying novel compds. with neurochem. and pharmacol. properties similar to those of clozapine. The binding profile at D2 like, 5-HT1A, and 5-HT2A receptors of title compds. was determined. Modifications made in the Ph rings of the parent compound produced congeners endowed with a broad range of binding affinities for DA D2 like, serotonin 5-HT1A, and 5-HT2A receptors, with IC50 values ranging from 25 to >10 000 nM. As for the modification of the piperazine N4-Ph ring, the affinities for both D2 like and 5-HT1A receptors were progressively increased by introduction of ortho-methoxy and ethoxy groups. Data revealed the presence of a para-chloro substituent to be associated with a relatively high affinity and substantial selectivity for D2 like receptors, whereas the meta-chloro analog exhibited preferential affinity for 5-HT1A receptors. A quant. structure-affinity relation anal. of the measured binding data resulted in regression equations that highlighted substituent physicochem. properties modulating the binding to subtypes 1A and 2A of serotonin 5-HT receptors but not to D2 like receptors. Thus, besides an electron-withdrawing field effect and ortho substitution, which both influence binding to serotonin 5-HT receptor subtypes, though to a different extent as revealed by regression coeffs. in the multiparametric regression equations, the affinity of congeners to 5-HT1A receptors proved to be linearly correlated with volume/polarizability descriptors, whereas their affinity to 5-HT2A receptors correlated with lipophilicity constns. through a parabolic relation. 1-[(1,2-Diphenyl-1H-4- imidazolyl)methyl]-4-(2-methoxyphenyl)piperazine (I), with a D2/5-HT1A IC50 ratio of .apprx.1, was selected for a further pharmacol. study. In rats, the i.p. administration of compound I, like that of clozapine, induced an increase in the extracellular concentration of DA measured in the medial prefrontal cortex. Furthermore, I and clozapine each inhibited GABA-evoked Cl- currents at recombinant GABAA receptors expressed in Xenopus oocytes. These findings suggest that compound I may represent an interesting prototype of a novel class of drugs endowed with a neurochem. profile similar to that of atypical antipsychotics.


IT 475596-0C-2P 475596-04-4P 475596-06-6P  
 475596-07-7P 475596-09-9P 475596-11-3E  
 475596-12-4P 475596-13-5P 475596-14-6P  
 475596-15-7P 475596-16-8P 475596-17-9P  
 475596-18-0P 475596-19-1P 475596-20-4P  
 475596-21-5P 475596-22-6P 475596-23-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structure activity relationships of phenylpiperazines with clozapine-like mixed activities at dopamine D2, serotonin, and GABAA receptors)


RN 475596-02-2 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 475596-04-4 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-06-6 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-07-7 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(4-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-09-9 CAPLUS

CN Methanone, [4-(2-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-11-3 CAPLUS

CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-12-4 CAPLUS

CN Methanone, [4-(4-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-13-5 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-14-6 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-15-7 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 475596-16-8 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 475596-17-9 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-18-0 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-19-1 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 475596-20-4 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-ethoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-21-5 CAPLUS

CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl] [4-phenyl-1-piperazinyl]- (CA INDEX NAME)




RN 475596-22-6 CAPLUS

CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl] [4-(2-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 475596-23-7 CAPLUS  
 CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-ethoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:505370 CAPLUS Full-text

DOCUMENT NUMBER: 81:105370

ORIGINAL REFERENCE NO.: 81:16667a,16670a

TITLE: Heterocyclization of  $\alpha$ -acylamino amides. III. Properties of 5-aminooxazoles

AUTHOR(S): Clerin, Daniel; Fleury, Jean P.

CORPORATE SOURCE: Lab. Chim. Org. Gen., Ec. Super. Chim., Mulhouse, Fr.

SOURCE: Bulletin de la Societe Chimique de France (1974), (1-2, Pt. 2), 211-17

CODEN: BSCFAS; ISSN: 0037-8968

DOCUMENT TYPE: Journal

LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB Treatment of 5-amino-2-aryl(or alkyl)oxazoles (I; R<sub>2</sub>N = piperidino, 1-pyrrolidinyl, morpholino; R<sub>1</sub> = Ph, p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, p-MeC<sub>6</sub>H<sub>4</sub>, Me) with electrophiles gave: with H<sub>3</sub>O<sup>+</sup>, R<sub>2</sub>NCOCH<sub>2</sub>NHCOR<sub>1</sub>; with (CF<sub>3</sub>CO)<sub>2</sub>I, 4-CF<sub>3</sub>CO derivs. of I; with PhNCO and PhNCS, 4-PhNHCO and 4-PhNCS derivs. of I; with arenediazonium salts, 4-position addition products, some of which rearranged to s-triazoles; and with sulfonyl azides, R<sub>2</sub>SO<sub>2</sub>N<sub>3</sub> (R = Me, p-MeC<sub>6</sub>H<sub>4</sub>), cycloaddn. products which rearranged with N elimination, then reacted with a second mol. of I to give II. When I had a Me group in the 4-position, reaction with arenediazonium salts opened the ring.


IT 53423-03-3P 53423-04-4P 53423-19-1P

53423-20-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 53423-03-3 CAPLUS

CN Morpholine, 4-[(1,5-diphenyl-1H-1,2,4-triazol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 53423-04-4 CAPLUS

CN Morpholine, 4-[[1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 53423-19-1 CAPLUS

CN Piperidine, 1-[[5-(4-nitrophenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 53423-20-4 CAPLUS

CN Piperidine, 1-[[1-(4-methylphenyl)-5-(4-nitrophenyl)-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)







ORIGINAL REFERENCE NO.: 75:23941a,23944a  
 TITLE: Carboxamides and carbohydrazides of  
 4,5-diphenyloxazole  
 INVENTOR(S): Marchetti, Enzo  
 PATENT ASSIGNEE(S): Istituto Farmacologico Serono S.p.A.  
 SOURCE: Ger. Offen., 17 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE        |
|------------------------|------|----------|-----------------|-------------|
| DE 2110363             | A    | 19710916 | DE 1971-2110363 | 19710304    |
| CH 555846              | A    | 19741115 | CH 1971-2839    | 19710226    |
| US 3869455             | A    | 19750304 | US 1971-119832  | 19710301    |
| CA 949580              | A1   | 19740618 | CA 1971-106905  | 19710304    |
| FR 2085675             | A5   | 19711231 | FR 1971-7751    | 19710305    |
| FR 2085675             | A1   | 19711231 |                 |             |
| JP 50004663            | B    | 19750222 | JP 1971-11584   | 19710305    |
| GB 1293702             | A    | 19721025 | GB 1971-1293702 | 19710419    |
| US 3925404             | A    | 19751209 | US 1973-353675  | 19730423    |
| PRIORITY APPLN. INFO.: |      |          | IT 1970-21550   | A 19700305  |
|                        |      |          | US 1971-119832  | A3 19710301 |

GI For diagram(s), see printed CA Issue.  
 AB Title compds. (I), analgesics and central nervous system depressants, were prepared from I (R=OEt or OMe) by aminolysis or hydrazinolysis, resp., or by saponification and reaction with amines or hydrazines, resp. Thus, I (n=0, R=OEt) was refluxed 24 hr with Et2NH to give 73% I (n=0, R=NEt2). Similarly prepared were 15 addnl. I, e.g. (n and R given): 0, NHNMe2; 1, NHMe; 1, morpholino; 2, NHH2.  
 IT 34015-88-8P 34015-89-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 34015-88-8 CAPLUS  
 CN Morpholine, 4-[(4,5-diphenyl-2-oxazolyl)carbonyl]- (8CI) (CA INDEX NAME)



RN 34015-89-9 CAPLUS  
 CN Pyrrolidine, 1-[(4,5-diphenyl-2-oxazolyl)carbonyl]- (8CI) (CA INDEX NAME)



L3 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:131227 CAPLUS Full-text

DOCUMENT NUMBER: 55:131227

ORIGINAL REFERENCE NO.: 55:24729e-1

TITLE: Action of organomagnesium compounds, piperidine, and

aromatic thiols on 4-arylozo-2-phenyloxazolin-5-ones

AUTHOR(S): Asker, Wafia; Elagroudi, Zien E.

CORPORATE SOURCE: Cairo Univ., Giza, Egypt

SOURCE: Journal of Organic Chemistry (1961), 26, 1440-3

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 55:131227


GI For diagram(s), see printed CA Issue.

AB The action of excess R'MgX on RNHN:C.N:CPh.O.CO (I) gave 1H-1,2,4-triazoles, RN.CPh:N.C(CR'2OH):N (II). Thus, adding 1 g. I (R = Ph) in 50 ml. C6H6 to PhMgBr (from 0.9 g. Mg and 9 g. PhBr in 50 ml. Et2O), refluxing the mixture 3 hrs., keeping it overnight at 25°, decompg, it with saturated aqueous NH4Cl, extracting with Et2O, evaporating the dried Et2O extract, and triturating the residue with petr. ether gave 60% II (R and R' = Ph), m. 180°. The appropriate I and R'MgBr gave the following II (R, R', % yield, and m.p. given): Ph, p-MeC6H4, 70, 189°, o-MeC6H4, Ph, 60, 152°; p-MeC6H4, Ph, 55, 145°; β-C10H7, Ph, 50, 201°. The products turned red with H2SO4. The action of piperidine on I caused a rearrangement to 1H-1,2,4-triazoles, RN.CPh:N.C(CONC5H10):N (III). Thus, adding 0.5 g. appropriate I to 0.5 ml. distilled. C5H10NH, shaking the mixture 15 min. to a clear solution, keeping it overnight at room temperature, triturating with hot petr. ether, and crystallizing the solids from dilute alc. gave the following III (R, % yield, m.p. given): Ph, 94, 193°; o-MeC6H4, 90, 127°; p-MeC6H4, 82, 141°; β-C10H7, 77, 130°. A similar rearrangement was observed from the action of aromatic thiols on I to also give 1 H-1,2,4-triazoles, RN.CPh: N.C(COSR'):N (IV). Thus, heating 1 g. I and 1 g. R'SH at 110 1.5 hrs., cooling, triturating with petr. ether, and crystallizing the residue from EtOH gave the following IV (R, R', % yield, m.p. given): Ph, Ph, 41, 146°; Ph, p-MeC6H4, 62, 195°; o-MeC6H4, p-MeC6H4, - 55, 181; p-MeC6H4, p-MeC6H4, 41, 177°; β-C10H7, p-MeC6H4, 46, 183°. IT 111384-11-3P, Piperidine, 1-(1,5-diphenyl-1H-1,2,4-triazol-3-ylcarbonyl)- 115181-88-7P, Piperidine, 1-[5-phenyl-1-p-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 115163-48-9P, Piperidine, 1-[5-phenyl-1-o-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- RL: PREP (Preparation)

(preparation of)


RN 111384-11-3 CAPLUS

CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-1-piperidinyl- (CA INDEX NAME)




RN 115101-88-7 CAPLUS

CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 115163-48-9 CAPLUS

CN Methanone, [1-(2-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 07:48:08 ON 09 OCT 2008